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ABBREVIATIONS 
AD                           alzheimer’s disease 
Akt                           serine/threonine kinase 
AL                            autophagolisosomes 
ALS                         amyotrophic lateral sclerosis 
APP                         amyloid precursor protein         
APP-CTFs               amyloid precursor protein C-terminal fragments 
APP-FL                   amyloid precursor protein full length  
ASM                        acid sphingomyelinase 
ATF                         activating transcription factor 
ATG                        autophagy realated protein 
BAPTA-AM           1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl 
                                 ester) 
Bcl-2                       B-cell lymphoma 2 
BSA                         bovine serum albumin  
cDNA                      complementary deoxyribonucleic acid  
CerS                        ceramide synthase  
CERT                      ceramide transfer protein 
CMA                       chaperone-mediated autophagy 
CNS                        central nervous system 
DMSO                    dimethyl sulfoxide 
DUBs                      deubiquitinating enzymes 
DRAM                    DNA damage-regulated autophagy modulator protein 
EGFP                      enhanced green fluorescent protein 
eIF2α                      eukaryotic initiation factor 2 alpha 
EM                          electron microscopy 
ER                           endoplasmatic reticulum 
GAP-43                   growth associated protein 43 
GFAP                      glial fibrillary acidic protein 
GFP                         green fluorescent protein 
GPBP                      goodpasture antigen binding protein 
HD                          Huntington’s disease 
HDAC                     histone deacetylase 
HRP                         horseradish peroxidase 
ICF                          immunocitofluorescence 
IHC                         immunohistochemestry 
IHF                          immunohistofluorescence 
IP                             immunoprecipitation 
IRE1                        inositol requiring 1 
Jnk                           c-Jun N-terminal kinase 
L                              lysosome 
LAMP-2                  lysosomal associated membrane protein 2 
LC3                         microtubule-associated protein 1A/1B-light chain 3 
LIR                          LC3-interacting region 
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MG-132                  N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal 
mRNA                    messenger ribonucleic acid  
mRFP                     monomeric red fluorescent protein 
mTOR                     mammalian target of rapamycin 
MUNC18                mammalian uncoordinated 18 
NCS1                      neuronal calcium sensor 1 
NeuN                       neuronal nuclei 
NPC                        Niemann-Pick disease, type C 
OQ                          other quadrant 
P                              phagophore 
PBS                         phosphate buffer saline 
PCR                         polymerase chain reaction 
PD                           Parkinson’s disease 
PDGF                      platelet-derived growth factor  
PE                            phosphatidylethanolamine 
PERK                      protein kinase RNA-like endoplasmatic reticulum kinase 
PFA                         paraformaldehyde 
PI3K                        phosphatidylinositol-4,5-biphosphate 3-kinase 
PKB                        protein kinase B 
PLP                         pyridoxalphosphate 
PSD95                     postsynaptic density protein 95         
S1P                          sphingosine 1-phosphate 
S1PR                       sphingosine 1-phosphate receptor 
SK                           sphingosine kinase 
SL                            sphingolipid 
SM                           sphingomyelin 
SNAP25                  synaptosome associated protein 25kDa 
SNARE                   SNAP (soluble NSF attachment protein) receptor 
SNCA                      synuclein alpha 
Sph                          sphingosine 
SPL                          sphingosine 1-phosphate lyase 
SPP                          sphingosine 1-phosphate phosphohydrolase 
SPT                          serine palmitoyltransferase 
SQSTM1                  sequestosome 1 
SVs                           synaptic vesicles 
THI                           2-acetyl-4-tetrahydroxybutyl imidazole 
TQ                            targeted quadrant 
UBA                         ubiquitin-associated 
UPR                          unfolded protein response 
UPS                          ubiquitin-proteasome system  
USP14                      ubiquitin-specific protease 14 
UVRAG                   UV radiation resistance associated gene 
VAMP2                    vesicle-associated membrane protein 2 
WB                           western blotting
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ABSTRACT 
 
The bioactive lipid sphingosine 1-phosphate (S1P) is a degradation product of sphingolipids that 
are particularly abundant in neurons. It was shown previously that neuronal S1P accumulation is 
toxic leading to ER-stress and an increase in intracellular calcium. To clarify the neuronal 
function of S1P, a brain-specific knockout mouse model was generated, in which S1P-lyase 
(SPL), the enzyme responsible for irreversible S1P cleavage was inactivated (SPLfl/fl/Nes mice).  
SPL cleaves S1P into ethanolamine phosphate, which is directed towards the synthesis of 
phosphatidylethanolamine (PE) that is an anchor to autophagosomes for LC3-I. In the brains of 
SPLfl/fl/Nes mic significantly reduced PE levels were detected. Accordingly, autophagy alterations 
involving decreased conversion of LC3-I to LC3-II and increased beclin-1 and p62 levels were 
apparent. Alterations were also noticed in downstream events of the autophagic-lysosomal 
pathway like increased levels of lysosomal markers and aggregate prone proteins such as amyloid 
precursor protein, α-synuclein and tau protein. Genetic and pharmacological inhibition of SPL in 
cultured neurons promoted these alterations while addition of PE was sufficient to restore LC3-I 
to LC3-II conversion, and control levels of p62, APP and α-synuclein. Rapamycin, which is an 
agonist of autophagy by inhibition of mTOR kinase, had no effect on autophagy in neuronal 
cultures from SPLfl/fl/Nes mice suggesting that the impaired autophagy seen in SPLfl/fl/Nes mice is 
mTOR independent. Electron and immunofluorescence microscopy showed accumulation of 
unclosed phagophore-like structures, reduction of autophagolysosomes and altered distribution of 
LC3 in SPLfl/fl/Nes brains. Experiments using mRFP-EGFP-LC3 provided further support for 
blockage of the autophagic flux at initiation stages upon SPL deficiency due to PE paucity. 
Developmental ablation of SPL in the brain (SPLfl/fl/Nes) caused marked accumulation of S1P and 
sphingosine. These changes in lipid composition lead to morphological, molecular and behavioral 
abnormalities. We observed altered presynaptic architecture including a significant decrease in 
number and density of synaptic vesicles (Mitroi et al. in press), and decreased expression of 
several presynaptic proteins in hippocampal neurons from SPLfl/fl/Nes mice. At the molecular level, 
accumulation of S1P induced a calcium mediated activation of the ubiquitin-proteasome system 
(UPS) which resulted in a decreased expression of the deubiquitinating enzyme USP14 and 
several presynaptic proteins. Upon inhibition of proteasomal activity, expression of USP14 and 
of preysnaptic proteins were restored. In addition, these mice displayed cognitive deficits. 
These findings identify S1P metabolism as a novel player in modulating synaptic architecture, 
and emphasize a formerly overlooked direct role of SPL in neuronal autophagy. 
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ZUSAMMENFASSUNG 
Das bioaktive Lipid Sphingosin-1-phosphat (S1P) ist ein Abbauprodukt von Sphingolipiden, die 
besonders reichlich in Neuronen vorkommen. Es wurde bereits infrüheren Studien  gezeigt, dass 
die Akkumulation von S1P neurotoxisch ist. Sie bewirkt   eine Zunahme des intrazellulären 
Calciums und löst ER-Stress aus. Um die neuronale Funktion von S1P weiter aufzuklären, wurde 
eine gehirnspezifische Knockout-Maus erzeugt, bei der S1P-Lyase (SP)L, das Enzym welches die 
irreversible S1P Spaltung katalysiert, inaktiviert wurde (SPLfl/fl/Nes Mäuse). 
SPL spaltet S1P in Ethanolaminphosphat, das zur Synthese von Phosphatidylethanolamin (PE) 
genutzt wird. PE verankert LC3-I in Autophagosomen als LC3-II. In den Gehirnen von SPLfl/fl/Nes 
Mäusen wurden deutlich reduzierte PE Spiegel beobachtet. Als Folge davon war die verminderte 
Umwandlung von LC3-I zu LC3-II signifikant reduziert. Des Weiteren wurde  eine erhöhte 
Expression von Beclin-1 und p62beobachtet. Veränderungen wurden auch in nachgelagerten 
Ereignisse im autophagasomal-lysosomalen Weg beobachtet. Neben einer Erhöhung an 
lysosomalen Markern, kam es auch zu einem Anstieg von Aggregat anfälligen Proteinen wie 
Amyloid-Vorläufer-Protein, α-Synuclein und Tau-Protein in Gehirnen der SPLfl/fl/Nes Mäuse.. 
Sowohl die genetische als auch die pharmakologische Hemmung der SPL in kultivierten 
Neuronen führten zu den gleichen  Veränderungen , während die Zugabe von PE ausreichend war 
um sowohl die LC3-I zu LC3-II-Konvertierung als auch den Gehalt an p62, APP und α-
Synuclein auf Kontrollniveau wieder herzustellen. Rapamycin, welches    durch die Hemmung 
der mTOR-Kinase als Autophagieantagonist fungiert, hatte keinen Effekt auf die Autophagie in 
SPL-defizienten Neuronen. Dieses Ergebnis zeigt dass die durch das Ausschalten von SPL 
fehlerhafte Autophagie mTOR unabhängig ist. Mit Hilfe der Elektronen- und 
Immunfluoreszenzmikroskopie konnte zudem eine Akkumulation von  noch nicht vollständig 
geschlossenen Phagophorartigen Strukturen, eine Reduzierung der Autophagolysosomen sowie 
eine veränderte Verteilung von LC3 in SPLfl/fl/Nes Gehirnen gezeigt werden. Unter Verwendung 
von mRFP-EGFP-LC3 konnte ein zusätzlicher Beweis  für die Blockierung des Autophagie-
Flusses bei  SPL-Defizienz in Neuronen  aufgrund eines PE-Mangelserbracht werden. 
Die entwicklungsabhängige Ablation von SPL im Gehirn  verursacht auch eine deutliche 
Zunahme von S1P und Sphingosin. Diese Veränderungen in der Lipidzusammensetzung führen 
zu morphologischen, molekularen und Verhaltensauffälligkeiten. Wir beobachteten 
Veränderungen der präsynaptischen Architektur einschließlich einer signifikanten Abnahme der 
Anzahl und Dichte von synaptischen Vesikeln (Mitroi et al. in press) sowie eine verminderte 
Expression mehrerer präsynaptischen Proteine in hippocampalen Neuronen aus SPLfl/fl/Nes 
Mäusen. Auf molekularer Ebene, induzierte die Akkumulation von S1P eine Calcium-vermittelte 
Aktivierung des Ubiquitin-Proteasomalen-Systems (UPS), die zu einer verminderten Expression 
des deubiquitinierenden Enzyms USP14 und einiger präsynaptischen Proteine führte. Durch 
Hemmung der proteasomalen Aktivität, konnte sowohl die Expression von USP14 als auch jene 
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derpräysnaptischen Proteine wiederhergestellt werden. Darüber hinaus zeigten diese Mäuse 
kognitive Defizite. 
Diese Ergebnisse identifizieren eine neue Rolle des S1P Stoffwechsels bei der Modulation der 
synaptischen Architektur und zeigen erstmalig eine vormals übersehene Bedeutung der SPL für 
die neuronale Autophagie. 
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1. INTRODUCTION 
 
Sphingosine 1-phosphate (S1P), sphingosine and ceramide are important metabolites of the 
sphingolipid network that have emerged as bioactive signaling molecules mediating critical 
cellular functions (Hannun et al. 2008). S1P is an evolutionarily conserved catabolic intermediate 
of sphingolipid metabolism that has been suggested as regulate crucial functions in the brain 
including neural development, differentiation and survival (Mizugishi et al. 2005, van Echten-
Deckert et al. 2014). Its deficiency has resulted in embryonic lethality associated with disturbed 
neurogenesis including neural tube closure (Mizugishi et al. 2005). On the other hand its 
accumulation has turned out to be neurotoxic leading to neuronal death (Hagen et al. 2009, Hagen 
et al. 2011). Alternatively, S1P is proposed as a neuroprotective factor early lost in the 
pathogenesis of Alzheimer’s (Couttas et al. 2014).  
The dynamic balance of S1P, which is maintained by sphingosine kinases (SK1 and SK2) 
catalyzing its formation, and S1P phosphatases (SPP1 and SPP2) and S1P-lyase (SPL), 
catalyzing its degradation, is a critical determinant of S1P associated cellular functions (Spiegel 
et al. 2003). In particular, the diverse roles of S1P in autophagy are increasingly being recognized 
(Taniguchi et al. 2012, Harvald et al. 2015). Ethanolamine phosphate, derived from the 
breakdown of S1P by SPL, can be used in the synthesis of PE, an abundant membrane lipid. 
However, in most cell types, redirection of S1P degradation by SPL toward 
phosphoethanolamine formation does not constitute the major pathway for de novo PE synthesis. 
Autophagy competes for a common PE pool with major cellular PE-consuming pathways 
(Wilson-Zbinden et al. 2015). Autophagy is crucial for the survival of post-mitotic cells with high 
energy demands like neurons (Nixon 2013). It is employed by neurons not only for homeostatic 
and waste-recycling functions but also as an effective strategy for eliminating aggregate prone 
proteins, normally diluted by cell division in mitotic cells (Komatsu et al. 2006). Accordingly, 
defective autophagy is often associated with neuronal dysfunction and enhanced autophagy in 
neurons is currently being focused on, as an approach in combating neurodegenerative diseases 
(Hara et al. 2006, Komatsu et al. 2006, Menzies et al. 2015). Recent reports have deciphered how 
S1P related autophagic pathways might affect neurodegeneration (Moruno Manchon et al. 2015). 
These controversial findings point to a tight regulation of S1P levels in the brain. 
                                                                                                                  Introduction 
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S1P accumulation in SPL-deficient neurons has been associated with increased cytosolic calcium 
levels (Hagen et al. 2011) and ER-stress (Hagen-Euteneuer et al. 2012), which has mediated 
apoptotic neuronal death (Hagen et al. 2011). Based on these findings and due to early postnatal 
death of systemic SPL knockouts (Hagen-Euteneuer et al. 2012), it was assumed that brain-
specific ablation of SPL might serve as a tool for clarifying the role of neuronal S1P. Therefore a 
mouse model was generated, with the developmental neural-specific ablation of SPL and its 
consequences explored.  
  
1.1 Sphingolipids 
 
1.1.1 Sphingolipid metabolism 
 
Sphingolipids (SLs) represent a major class of natural lipids consisted of a sphingoid base 
backbone, and are ubiquitous constituents of membranes in eukaryotes. An essential molecule in 
sphingolipid biology is ceramide (Chen et al. 2010) formed of sphingosine N-acylated with fatty 
acids. A range of charged, neutral, phosphorylated, or glycosylated moieties are attached to 
ceramide further creating complex sphingolipids (Merrill et al. 2007). One example is phosphoryl 
choline which attached to ceramide makes sphingomyelin, the most abundant mammalian 
sphingolipid. 
During the last couple of decades the biochemical pathways of SL metabolism (Huwiler et al. 
2000, Futerman et al. 2005) and the intracellular compartments of synthesis and degradation 
(endoplasmic reticulum (ER)/Golgi apparatus and lysosomes, respectively) have been broadly 
characterized (Futerman et al. 2005, Futerman 2006). 
SL synthesis starts with the condensation of serine and palmitoyl CoA by serine palmitoyl 
transferase (Hanada 2003) to form 3-keto-dihydrosphingosine, which is subsequently reduced by 
3-ketosphinganine reductase to produce dihydrosphingosine, followed by acylation by a 
(dihydro)-ceramide synthase (Lass or CerS) (Pewzner-Jung et al. 2006). Ceramide is formed by 
the desaturation of dihydroceramide (Causeret et al. 2000) (Fig.1). Ceramide may be degraded by 
one of many ceramidases (Galadari et al. 2006, Xu et al. 2006) forming sphingosine, which may 
be recycled into sphingolipid  pathways, or it can be phosphorylated by sphingosine kinases (Hait 
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et al. 2006), SK1 or SK2. The product S1P can be dephosphorylated back to sphingosine by 
specific intracellular S1P phosphatases (Johnson et al. 2003) and, also by non-specific 
extracellular and intracellular lipid phosphate phosphatases (Brindley 2004, Sigal et al. 2005). 
S1P can also be cleaved irreversibly by S1P lyase with generation of ethanolamine phosphate and 
hexadecenal (which can be oxidized to palmitate (reduced to palmitol and reused) (Bandhuvula et 
al. 2007). 
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Figure 1. Schematic view of sphingolipid metabolism. SPT, serine palmitoyl transferase; 3KSR, 3-
ketosphinganine reductase; CerS, ceramide synthases; Des, dihydroceramide desaturase; SMS, 
sphingomyelin synthases; SMases; sphingomyelinases; GCS, glucosylceramide synthase; GCase, 
glucocerebrosidase; CDases, ceramidases; SKs, sphingosine kinases; SPPs, sphingosine-1-phosphate 
phosphatases; SPL, sphingosine-1-phosphate lyase (Bedia et al. 2011). 
 
 
 
1.1.2 Sphingosine 1-phosphate lyase 
 
The first report of cloning of an SPL gene was published in 1997 (J.D. Saba 1997). In this article, 
the Saccharomyces cerevisiae DPL1 (DHS1P lyase) gene was identified by its ability to suppress 
sphingosine-induced growth inhibition. Subsequently, SPL homologs from Mus musculus, Homo 
sapiens, Drosophila melanogaster, Caenorhabditis elegans, Dictyostelium discoideum and 
Leishmania major were identified and confirmed by means of biochemical assay  as encoding 
functional SPL enzymes and functional complementation of yeast dpl1 mutants (J. Zhou 1998, 
P.P. Van Veldhoven 2000, G. Li 2001, D.R. Herr 2003, J. Mendel 2003, K. Zhang 2007). To 
date, genomic sequencing has revealed the existence of putative SPL genes in a wide variety of 
organisms including fungi, plants and mammals. The human SPL gene, Sgpl1, encodes a 
predicted protein of 568 amino acids with a molecular mass of 63.5 kDa (P.P. Van Veldhoven 
2000). The amino acid sequence of the murine SPL homolog displays 84% identity and 92% 
similarity to human SPL. Similarity in primary sequence is also found in SPL homologs from D. 
melanogaster, L. major, C. elegans, D. discoideum and S. cerevisiae. 
Immunofluorescence and subcellular fractionation studies have confirmed the primary location of 
SPL within the endoplasmic reticulum (ER), although the possibility that some SPL may localize 
to other organelles has not been definitively ruled out (P.P. Van Veldhoven 2000, M. Ikeda 2004, 
U. Reiss 2004). It has not yet been established just how SPL is specifically localized in the ER, 
although removal of the first 58 amino acids leads to its expression in the soluble fraction of 
Escherichia coli (P.P. Van Veldhoven 2000). SPL has not been found in serum, in plasma or in 
the extracellular space, and there are no reports of ecto-enzymes or secreted isoforms. Thus, SPL 
seems to be restricted to the intracellular environment. This allows SPL to act like an S1P “sink”, 
creating a gradient between circulating and tissue S1P levels that has physiological importance 
(Fyrst et al. 2008). 
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SPL function appears to be critical for mammalian development. Sgpl1 expression has been 
observed throughout the development of mouse embryos (M. Ikeda 2004, Schmahl J 2007). 
Homozygous Sgpl1 knockout mice do not survive beyond 3–4 weeks after birth, and they exhibit 
significant growth failure and anemia (Serra et al. 2010). Several congenital defects have been 
reported, including vascular abnormalities, skeletal defects, thoracic malformation of the 
sternum, ribs and vertebrae, and renal abnormalities (Fyrst et al. 2008). Embryonic fibroblasts 
from Sgpl1 knockout mice have been shown to have migration defects in vitro (Schmahl et al. 
2007). These vascular and cell migration defects are reminiscent of pathological changes 
observed in PDGF receptor and S1P1 receptor knockout mice (Y. Liu et al. 2000). Together with 
the identification of Sgpl1 as a downstream target of PDGF signaling, this information suggests 
that SPL may play a role in the regulation of mammalian angiogenesis and other developmental 
processes (Fyrst et al. 2008). 
 
1.1.3 Involvement of sphingolipids in neurodegenerative diseases  
 
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by blood-brain barrier 
break down, immune cell infiltration of the CNS, demyelination, astrogliosis, and 
neurodegeneration (Pelletier et al. 2012). S1P signaling activity is relevant to disease 
pathogenesis, as demonstrated by the efficacy of FTY720, a structural analog of S1P, in the 
treatment of relapsing-remitting MS (Brinkmann et al. 2010). S1P action likely occurs at multiple 
cellular sites within the immune, vascular, and nervous systems (Brinkmann et al. 2010).  
Intracellular aggregation and protein misfolding are characteristics of many late-onset 
neurodegenerative diseases, also known as proteinopathies. These proteinopathies include 
Alzheimer’s disease (AD), Parkinson’s disease (PD), tauopathies and Huntington’s disease (HD), 
and the proteins that accumulate are thought to be toxic. This belief is supported by 
overexpression in  mouse models of HD, the presence of autosomal dominant tauopathies caused 
by mutations in the gene encoding tau, and PD due to triplication of the α-synuclein (SNCA) 
locus (Rubinsztein 2006). Even though inducing clearance of intracellular aggregate-prone 
proteins could constitute a therapeutic strategy, compromised clearance may increase or 
contribute to disease by increasing levels of key substrates such as aggregate-prone proteins 
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(Hara et al. 2006, Komatsu et al. 2006) and dysfunctional mitochondria (Kim et al. 2011), 
enhancing susceptibility to cell death (Boya et al. 2005, Ravikumar et al. 2006); and disturbing 
flux through the ubiquitin-proteasome system (Korolchuk et al. 2009). The role of lipid 
homeostasis in the brain, particularly that of membrane lipids, in AD pathogenesis has been 
recognized and considered in multiple studies (Lane et al. 2005, Walter et al. 2013). Neuronal 
membranes contain a highly specific and characteristic pattern of complex sphingolipids and 
therefore is it not surprising that neuronal function and survival is dependent on the metabolism 
of these lipids (van Echten-Deckert et al. 2014). Neuronal levels of S1P are tightly regulated at 
very low concentrations in the picomolar range (Hagen et al. 2009, Hagen-Euteneuer et al. 2012). 
A direct role of S1P in neuronal Aβ generation has been reported recently (Takasugi et al. 2011). 
Moreover, SPL knock-out cells showed strong accumulation of APP and potentially 
amyloidogenic APP C-terminal fragments, which have been associated with impaired lysosomal 
degradation (Karaca et al. 2014). 
The integral component of the brain is formed by sphingolipids and therefore a proper 
sphingolipid homeostasis is crucial for the normal functioning of neurons. Several neurological 
diseases like Niemann-Pick disease (type I), Gaucher’s disease, and Tay-Sacks disease result 
from the dysfunction of enzyme activities that handle complex sphingolipids (Rao et al. 2008). 
Niemann-Pick disease is a lysosomal storage disease, caused by mutations in the Sphingomyelin 
phosphodiesterase genes and is accompanied by a group of fatal inherited metabolic disorders. 
The complete or partial deficiency of acid sphingomyelinase (ASM) resulting from these 
mutations causes cell death due to the accumulation of sphingomyelin. Ledesma et al. (Ledesma 
et al. 2011) reviewed the neuronal impact in the acid sphingomyelinase knockout mouse model. 
Besides changes in the lipid content of neurons, this also includes a possible impairment in the 
neuronal signaling that may lead to Purkinje cells death, altered axonal polarity, altered calcium 
homeostasis, abnormal endocytosis function, and even an increased susceptibility to infection 
because of dysfunctional microglia (Ledesma et al. 2011). Although the primary defect in NPC 
(Niemann-Pick disease, type C) is related to cholesterol transport in endosomal-lysosomal 
compartments, SLs also accumulate in these compartments. Thus NPC might also be classified as 
a SL storage disorder (van Echten-Deckert et al. 2012). In addition, brains of NPC patients also 
showed accumulation of amyloidogenic APP CTFs and Aβ42 as compared to control brains (Jin 
et al. 2004). To sum up, evidence suggests that even minor changes in sphingolipid balance may 
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play an essential role in the development of neurodegenerative diseases, including Alzheimer’s 
disease (Mielke et al. 2010), amyotrophic lateral sclerosis (Cutler et al. 2002), Parkinson’s 
disease (France-Lanord et al. 1997), and dementia (Haughey et al. 2004). 
 
1.2 Autophagy and ubiquitin-proteasome system 
 
Two major pathways accomplish regulated protein catabolism: the ubiquitin-proteasome system 
(UPS) and the autophagy-lysosomal system (Fig. 2). The UPS accomplishes selective 
degradation of short-lived proteins. Degradation by the proteasome is spatially and temporally 
controlled largely by highly specific targeting of proteins by conjugation with polyubiquitin 
chains (Ciechanover 2005). Autophagy is a cellular catabolic process used to maintain cellular 
homeostasis. It is responsible for the degradation and recycling of long-lived proteins, protein 
aggregates and damaged organelles, via autophagolysosomes (Ravikumar et al. 2010, Chen et al. 
2011). Recent studies have shown that autophagy also has additional functions, including 
organelle clearance, antigen presentation, elimination of microbes, in addition to regulation of 
development and cell death (Mizushima 2005). Autophagy occurs under basal conditions and it is 
stimulated by different types of cellular stress, such as nutrient starvation, oxidative stress, 
hypoxia, endoplasmic reticulum (ER) stress, mitochondrial damage, and is also stimulated by the 
application of treatment with some pharmacological agents (Kroemer et al. 2010). Three types of 
autophagy have been described: macroautophagy, microautophagy, and chaperone-mediated 
autophagy (CMA) (Klionsky 2005). Macroautophagy, more simply known as autophagy, occurs 
when cytoplasmic components are surrounded by double membrane structures called 
autophagosomes that mature by first fusing with late endosomes or by fusing directly with 
lysosomes in the formation of autolysosomes. In the final stage the autolysosome content, 
together with its inner membrane, is degraded by lysosomal hydrolases (Ravikumar et al. 2010, 
Chen et al. 2011). Microautophagy involves the direct engulfment of the cytoplasm on the 
lysosomal surface, while CMA translocates unfolded, soluble proteins directly across the limiting 
lysosomal membrane (Massey et al. 2006) (Fig. 2). The role of autophagy in recycling is 
complementary to that of the UPS, which degrades proteins to generate oligopeptides that are 
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subsequently degraded into amino acids, while replenishing the cell’s supply of free ubiquitin 
(Nedelsky et al. 2008). 
 
 
 
Figure 2. The ubiquitin-proteasome system (UPS) and autophagy are two major intracellular 
protein degradation systems. Proteasome-mediated degradation involves covalent addition of ubiquitin 
chains to target proteins followed by proteolytic cleavage through proteasome. Recent studies suggest that 
some ubiquitinated substrates could also be prone for the autophagy-lysosomal system. Multiple types of 
autophagy involve distinct routes in which cytoplasmic components are delivered for lysosome-mediated 
degradation. (1) Macroautophagy is a multistep process by which cytosolic components are engulfed by 
an isolation membrane to form autophagosomes that are delivered to lysosomes. (2) Microautophagy, 
cytosolic contents are directly engulfed by lysosomes. (3) Chaperone-mediated autophagy involves 
recognition of a peptide signal that induces receptor-mediated translocation into the lysosome (Nedelsky 
et al. 2008). 
 
1.2.1 Autophagy 
 
Autophagy is begun by the formation and elongation of a double-layered isolation membrane (the 
origin of which is not precisely known) called phagophore, which enwraps and sequesters parts 
of the cytoplasm containing autophagic substrates, to form autophagosomes. A set of Atg genes 
regulates the formation of autophagosomes, where Atg stands for autophagy-related. Atg genes 
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were originally discovered in yeast where the nomenclature was taken from Klionsky et al. 
(Klionsky et al. 2003). According to their function these can be grouped into the Atg1 complex 
regulating vesicle nucleation (Atg1, Atg13 and Atg17 controlling autophagosomal induction), the 
PI3K complex III (including phosphatidyl inositol 3-phosphate kinase vps34, Beclin 1 (Atg6 
orthologue) UVRAG (UV radiation resistance associated gene)), and two interconnected 
ubiquitin-like conjugation systems that mediate vesicle elongation and sealing. Formation of the 
Atg5-Atg12 conjugate is one of the first of these conjugation systems mediated by the E1-like 
enzyme, Atg7, and the E2-like enzyme, Atg10. The second of these systems involves conjugation 
of Atg8 (in mammalian cells also known as microtubule-associated protein 1 light chain 3, LC3) 
with the lipid, phosphatidylethanolamine, regulated by Atg7, along with Atg3, as the E2-like 
enzyme (Suzuki et al. 2007). After the formation of the autophagosome, Atg5-Atg12 conjugate is 
removed, while LC3 remains attached to the vesicle. Thus, LC3 serves as a reliable 
autophagosomal marker that can be used to evaluate the rates of autophagosome formation and 
degradation (Klionsky et al. 2008). Autophagosomes are transported along microtubules in a 
dynein-dependent manner and fuse with endosomes or fuse directly with lysosomes where 
autophagosomal contents are degraded by lysosomal hydrolases (Ravikumar et al. 2005). 
 
1.2.2 The ubiquitin-proteasome system (UPS) 
 
Proteins are targeted for degradation by the UPS via a series of enzymatic reactions that tag them 
with ubiquitin, a small 76-amino acid residue (Ciechanover et al. 1980, Hershko et al. 1980). 
UPS clients are marked by polyubiquitylation for transportation by a shuttling machinery, which 
is not very well understood, to proteasome, a specialized organelle, where proteins are degraded 
to oligopeptides, which are released into the cytoplasm or nucleoplasm. Oligopeptides can be 
further digested into amino acids by soluble peptidases. The specificity and selectivity of the 
ubiquitylation process is delineated by a combination of three types of enzymes (Hershko et al. 
1983). The initiation of the reaction is made by activating ubiquitin E1 enzymes, two of these 
known in mammals, and by transferring it onto E2 ubiquitin-conjugating molecules (it is thought 
that around 40 are encoded in the mammalian genome). One of several hundred E3 ligases, which 
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are capable of binding the ubiquitin-carrying E2 enzyme, selects a substrate, resulting in the 
transfer of the ubiquitin onto lysine residues (Pickart et al. 2004, Randow et al. 2009). As a result 
of this type of reaction, the substrate becomes monoubiquitylated in one or more places. For 
proteasomal targeting the initial modifications are insufficient, since ubiquitin itself contains 
lysine residues in positions 6, 11, 27, 31, 33, 48 and 63, that would be able to accept another 
ubiquitin moiety in a second round of ubiquitylation. This will lead to the generation of different 
types of polyubiquitin chains. For delivery to the proteasome, it is believed that at least four 
ubiquitin chains are ideal (Thrower et al. 2000), interconnected via K48 residues and 
characterized by a closed conformation (Fushman et al. 2010). The proteasome is a barrel–shaped 
proteolytic organelle found throughout the cell. It consists of a 20S central complex and two 19S 
lid complexes. The 19S complexes bind cargo-loaded shuttling proteins, deubiquitylate the 
substrates and control access to the six proteolytic sites of the inner core of the 20S subunit 
(Kopp et al. 1986, Lowe et al. 1995). The catalytic activities of the proteasome have different 
specificities, and are considered trypsin-, chymotrypsin- and peptidyl-glutamyl peptide-
hydrolyzing-like (Heinemeyer et al. 1997). Protein substrates have to be partially-unfolded prior 
to entry into the 20S subunit since the proteasomal catalytic pore is relatively narrow in size. 
Thus, protein complexes and aggregates can only be degraded if they are disassembled. This 
makes them unlikely substrates of proteasome (Nandi et al. 2006).  
Deubiquitinating enzymes (DUBs) remove covalently attached ubiquitin from proteins, thereby 
controlling substrate activity and/or abundance (Sowa et al. 2009). Mammalian proteasomes are 
associated with three DUBs: RPN11, UCH37, and USP14 (Lee et al. 2010, Nag et al. 2012). Both 
USP14 and UCH37 associate reversibly with the 19S regulatory particle, whereas RPN11 is an 
intrinsic subunit of the proteasome lid subcomplex of the 19S regulatory particle; therefore, the 
modulation of their functions may affect the proteasomal uptake of the protein substrate for 
degradation (Tian et al. 2014). USP14, in particular, can inhibit proteasomes in vitro, and also 
inhibits protein turnover in cells (Lee et al. 2010). 
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1.2.3 Presynaptic protein degradation by the ubiquitin proteasome system 
 
Some studies provide information about the function of UPS in the presynaptic terminals. One of 
these studies has shown that some components of the UPS, like E1 and the proteasome, are found 
in the presynaptic boutons at the neuro-muscular junction in Drosophila (Speese et al. 2003). 
Using a conditional fluorescent reporter of proteasome activity, these studies have demonstrated 
that the proteasome is active in these boutons. Proteasome inhibition provoked a 50% increase in 
excitatory junctional current amplitude when compared to controls. The rapid increase suggests a 
local degradation of proteins by the UPS. DUNC-13, a protein regulating synaptic vesicle 
priming seems to be involved in this process. Speese et al. (Speese et al. 2003) showed that 
DUNC-13 accumulates at the presynaptic site upon proteasome inhibition. Syntaxin-1 and 
synaptophysin, two other synaptic vesicle proteins involved in neurotransmitter release, are also 
regulated by UPS (Chin et al. 2002, Wheeler et al. 2002). At the presynaptic terminal 
deubiquitinating enzymes are also found. They can decrease the total content of ubiquitinated 
substrates within a matter of seconds (Chen et al. 2003). USP14, a deubiquitinating enzyme of 
the presynapse was reported to have been involved in the regulation of synaptic transmission 
(Bhattacharyya et al. 2012). Thus, an ataxic mouse model with a loss of functional mutation of 
USP14 exhibits decreased frequency and increased amplitude of miniature end plate potentials at 
the neuromuscular synapses (D'Amato et al. 1965). Hippocampal short-term plasticity, but not its 
long-term plasticity, is also impaired, which suggests that UPS activity and ubiquitin recycling 
are important modulators of neurotransmitter release and plasticity (Wilson et al. 2002).   
 
 
 
 
 
 
                                                                                                                  Introduction 
18 
 
1.2.4 Relationship between the proteasomal system and autophagy 
 
1.2.4.1 Ubiquitin as a unifying factor linking the UPS and selective autophagy 
 
Autophagy was believed to be a non-specific process that degrades cytoplasmic proteins and 
organelles in conglomerate, a situation that may occur during periods of starvation when cell 
survival depends on autophagy  (Ciechanover 2005). Organelles like the ER or mitochondria 
were the first evidence of selective autophagy, as early as in the 1970s, although further 
understanding of such selectivity was impossible until more recent insights into the molecular 
mechanisms of selective autophagy (Klionsky 2007). While there is still scant evidence for this 
process, it is assumed that, during selective autophagy, certain autophagic substrates may be 
specifically targeted for degradation, in the process of being randomly taken up along with an 
amount of cytoplasm. The importance of this issue becomes evident when we are aware that 
ubiquitylation plays a significant role as a signal of selective autophagy, just as in the ubiquitin 
proteasome pathway. Therefore, it might be tempting to consider that the degradation of cellular 
targets is regulated by ubiquitin in both the UPS and autophagic processes. Certainly, many 
proteins have been shown to be target substrates for both degradative systems. In some 
circumstances the ubiquitylated substrates, normally digested by the UPS, can also be degraded 
by autophagy, and vice versa (Fuertes et al. 2003, Fuertes et al. 2003, Wooten et al. 2008). 
Moreover, impairment of proteasomal activity was found to activate autophagy, thought to be a 
compensatory mechanism allowing the cell to reduce the levels of UPS substrates (Iwata et al. 
2005, Ding et al. 2007, Pandey et al. 2007, Milani et al. 2009). Nonetheless, the total contribution 
of autophagy to the degradation of the overall pool of ubiquitylated proteins in the cell is still 
unclear. It is also unknown whether ubiquitylation is an essential mechanism for targeting many 
proteins to autophagy. The exact type of ubiquitin modification recognized by each pathway 
seems to vary, although ubiquitylation may appear to function as a universal tag for substrate 
degradation via both catabolic systems. It is known that K48-linked polyubiquitin chains are 
targeted to the UPS and the substrates recognised by autophagosome-lysosome pathway are 
believed to be modified either by K63-linked chains (adopting a more open conformation than 
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K48 chains), or may simply be monoubiquitylated (Welchman et al. 2005). Thus, despite the use 
of ubiquitin in both catabolic pathways, the structural complexity of different polyubiquitin 
chains may be sufficient to maintain the selectivity and specificity of the UPS and autophagy in 
their substrates. However, some potential overlap may result from the incomplete specificity of 
the different adaptor molecules that have been thought to retrieve the ubiquitylated substrates of 
each degradative pathway. In this group, there are several proteins that seem to serve as linkers 
between ubiquitylated cargo and the phagophore, including p62 (also called SQSTM1/A170), 
NBR1 (neighbour of BRCA1 gene 1), HDAC6 (histone deacetylase 6) and Alfy  (Kirkin et al. 
2009). These proteins have the capacity to interact directly or indirectly with both ubiquitin and 
components of autophagic machinery, thus providing the type of link that would be provided by 
an adaptor molecule. The most established of these adaptors, p62, is itself an autophagy substrate 
that forms homo-oligomers to which ubiquitylated proteins are recruited via its UBA (ubiquitin 
associated) domain (Bjorkoy et al. 2005, Komatsu et al. 2007, Pankiv et al. 2007, Kirkin et al. 
2009). These complexes have been described as serving to sequester ubiquitylated substrates that 
are recognised by the autophagic machinery (p62 interacts directly with LC3 via a dedicated LIR 
motif (Pankiv et al. 2007)), and then engulfed and degraded (Bjorkoy et al. 2005, Kirkin et al. 
2009). The UBA domain of p62 seems to have a higher preference for monoubiquitin or 
polyubiquitin chains with open conformations (K63-linked), compared to those with a closed 
conformations (K48-linked) (Long et al. 2008). This may suggest a preference of autophagy for 
substrates tagged with single ubiquitin, short chains, or with longer K63 chains, and might also 
still allow K48 chain-tagged substrates to be recruited in autophagosomes, especially in 
circumstances where the UPS is compromised, and when the concentration of K48-
polyubiquitylated proteins is sufficient to allow such chains to interact effectively with p62 
(Fuertes et al. 2003, Long et al. 2008). A small accumulation of primarily K63-linked 
polyubiquitin-tagged proteins was observed in p62-deficient mouse tissues. The interpretation of 
this effect is complex, since p62 also appears to have a function as an adaptor in the proteasomal 
degradation of some ubiquitylated proteins. p62 appears to have a ubiquitin-independent role in 
the degradation of some autophagic substrates (Geetha et al. 2008, Wooten et al. 2008). 
Nevertheless, these studies are consistent with the notion that p62 can serve as an adaptor that is 
required for the autophagic degradation of ubiquitylated proteins (Kirkin et al. 2009, Kirkin et al. 
2009). 
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1.2.4.2 Impairment of the UPS is compensated by upregulation of autophagy 
 
One of the proposed links between the UPS and autophagy is based on the observation that 
impairment of the UPS leads to increased autophagic function (Iwata et al. 2005, Ding et al. 
2007, Pandey et al. 2007). This is a compensatory mechanism, allowing cells to reduce the 
accumulation of UPS substrates. Treatment of both cells and mice with rapamycin to upregulate 
autophagy has been demonstrated to protect against cell death caused by proteasome inhibition 
(Pan et al. 2008). Moreover increase of autophagy has been shown to protect against loss of 
proteasome activity in Drosophila (Pandey et al. 2007). Unfortunately, there is little consensus on 
the exact mechanism(s) of this cross-talk, as several potential explanations have been suggested. 
One possible mechanism involves the induction of the unfolded protein response (UPR) by the 
activation of endoplasmic reticulum (ER) stress, due to the accumulation of misfolded proteins. 
The UPR is an ER-to-nucleus signaling pathway that results in the transcriptional activation of a 
variety of genes, including those involved in protein folding and degradation in the ER. This 
pathway activation has been shown by a number of studies to also activate autophagy (reviewed 
in (Hoyer-Hansen et al. 2007)). There are diversities in the exact mechanics of this phenomenon, 
and it is most likely to depend on the cell type and stimulus for the UPR. Investigations into the 
direct link between proteasome inhibition, UPR and autophagy have been carried out in two 
studies using the proteasome inhibitor bortezomid. These studies demonstrate the importance of 
the transcription factor ATF4 in the upregulation of autophagy genes following proteasome 
inhibition (Milani et al. 2009, Zhu et al. 2010). However, the study of Zhu et al. (Zhu et al. 2010) 
suggests that the mechanism for increased ATF4 level is the activation of the PERK arm of the 
UPR requiring the phosphorylation of eIF2a, whereas Milani et al. (Milani et al. 2009) suggest 
that direct stabilization of the ATF4 protein due to the loss of proteasome activity, independent of 
the upstream activity of PERK, results in its increased activity (Milani et al. 2009). In addition 
these studies differ in the downstream targets of ATF4 action, showing on one hand an increase 
in ATG5 and ATG7 transcription (Zhu et al. 2010), and on the other hand in LC3 expression 
(Milani et al. 2009). Another study has suggested that compensatory autophagy upregulation 
following treatment with MG-132, or bortezomib, is mediated by the IRE1 arm of the UPR and 
its downstream target c-Jun NH2-terminal kinase (Jnk1) (Ding et al. 2007, Wei et al. 2008). Jnk1, 
                                                                                                                  Introduction 
21 
 
in turn, may induce autophagy by phosphorylation of Bcl-2, thereby disrupting its autophagy–
inhibitory interaction with Beclin 1 (Ding et al. 2007, Wei et al. 2008). Independently of the 
UPR, proteasome inhibition in dopaminergic neurons has been shown to induce autophagy via a 
mechanism requiring p53 (Du et al. 2009). The protective effect of the compensatory 
upregulation of autophagy in proteasome-inhibited cells has also been suggested to be dependent 
on HDAC6 (Iwata et al. 2005, Pandey et al. 2007). However, the role for HDAC6 in this process 
is not thought to be through signaling to increase autophagic flux, but rather through ensuring 
efficient delivery of substrates to the autophagic machinery for degradation. There is a general 
consensus about a compensatory role of autophagy following proteasomal inhibition, but the 
exact mechanisms of this link require further clarification (Fig. 3). These different mechanisms 
may not be mutually-exclusive and may also be of different importance in different cell types or 
at different time-points after the proteasome is inhibited.  
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Figure 3. Possible mechanisms of compensatory autophagic upregulation following UPS inhibition. 
Unfolded protein response, elevated levels of p53 and the increased aggregation of ubiquitylated proteins 
mediated by HDAC6, have all been implicated in the cross-talk between the UPS and autophagy 
(Korolchuk et al. 2010). 
 
1.2.4.3 Effect of autophagy on the UPS 
 
Genetic studies in mice demonstrated that inactivation of autophagy by the knockout of essential 
autophagic genes (Atg5 or Atg7) results in the accumulation and aggregation of ubiquitylated 
proteins (Hara et al. 2006, Komatsu et al. 2006). One interpretation is that ubiquitylated proteins 
could be degraded by autophagy, although it is currently unknown whether the type of 
polyubiquitin chains accumulating in autophagy-deficient tissues is consistent with the proposed 
specificity of autophagy for K63-linked polyubiquitin chains. The extent to which autophagy 
contributes to the degradation of the total pool of cellular ubiquitylated proteins, or whether the 
accumulation of ubiquitylated autophagic substrates can alone explain the profound accumulation 
of ubiquitin seen in autophagy-deficient mice. Another possibility is that autophagosomal clients 
that initially are not ubiquitylated, remain long enough in autophagy-deficient cells to eventually 
become modified by ubiquitin. Finally, autophagy impairment could impact on the flux through 
the UPS. Indeed, some findings support the latter hypothesis. Impaired autophagy was found to 
cause impaired degradation of specific UPS clients (Korolchuk et al. 2009, Korolchuk et al. 2009, 
Qiao et al. 2009). These data suggest that the decreased UPS flux in autophagy-compromised 
cells was not due to impaired catalytic activity of proteasomes isolated from them. Instead, it was 
found that the block in the UPS function is mediated by accumulation of p62, as its knockdown 
rescued the levels of UPS substrates in autophagy-deficient cells. In addition, overexpression of 
p62 alone was sufficient to inhibit the UPS, an effect partially dependent on its UBA domain. 
Since p62 competes with other ubiquitin-binding proteins involved in proteasomal degradation, 
like p97/VCP (valosin-containing protein), for binding to ubiquitylated proteins, it was proposed 
that elevated levels of p62 may deny such shuttling proteins access to ubiquitylated UPS 
substrates (Fig. 4) (Korolchuk et al. 2009, Korolchuk et al. 2009). These findings help to explain 
how knockout of p62 rescues the increased levels of soluble and aggregated ubiquitylated 
proteins observed in autophagy-deficient tissues (Komatsu et al. 2007). Thus, p62 has been 
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implicated in two different, but not mutually- exclusive, mechanisms of cross-talk between the 
UPS and autophagy. In the physiological state, where autophagy operates at normal rates, p62 
could serve to deliver ubiquitylated proteins for autophagosomal destruction (Bjorkoy et al. 2005, 
Pankiv et al. 2007, Kirkin et al. 2009). In contrast, in situations where autophagy becomes 
impaired (which occurs in a variety of pathological conditions, including certain 
neurodegenerative conditions, such as lysosomal storage disorders), p62 becomes a Trojan horse 
due to its binding (probably non-selectively because of elevated levels) to ubiquitylated proteins 
and preventing their delivery to the proteasome for degradation (Korolchuk et al. 2010). The lack 
of compensation for autophagy dysfunction by the UPS is in agreement with the fact that p62, 
when accumulating, oligomerizes and therefore would be too bulky to be a good substrate for the 
proteasome with its narrow catalytic pore. A special case of coordination between the two 
degradative systems comes from Goldberg and colleagues, who demonstrated that both the UPS 
and autophagy contribute to muscle atrophy in physiological conditions, like fasting, as well as in 
diseases characterized by muscle wasting (Zhao et al. 2007). In this case, coordinate upregulation 
of both catabolic pathways was induced by the FoxO3 transcription factor downstream of the 
IGF-1/PI3K/Akt signaling axis.  
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Figure 4. Inhibition of autophagy impairs the UPS function. p62, which accumulates due to autophagy 
blockade, binds ubiquitylated proteins and prevents their delivery to and degradation by the proteasome. 
Toxicity due to elevated levels of certain UPS substrates, like p53, and accumulation of ubiquitinated p62-
positive aggregates are the components of the autophagic deficiency phenotype (Korolchuk et al. 2010). 
 
1.2.5 Role of autophagy and the ubiquitin-proteasome system in neuroprotection 
 
First studies which provided evidence for the protective role of autophagy in the context of 
disease was initially provided by a series of in vitro studies demonstrating that disease-causing 
proteins are frequently degraded by autophagy. The neuroprotective role of autophagy was 
provided by a series of animal studies in which impairment of the autophagy-lysosomal system 
was consistently found to induce neurodegeneration. Knockout of cathepsin D, a lysosomal 
protease highly expressed in the nervous system, caused accumulation of autophagosomes and 
lysosomes with accompanying neural dysfunction and degeneration (Koike et al. 2000, Koike et 
al. 2005, Shacka et al. 2007). The importance of autophagy in neurodegeneration was further 
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underscored by two studies examining conditional knockout of autophagy in murine central 
nervous system. Deficiency of Atg5 or Atg7, both critical proteins for autophagosome formation, 
caused neurodegeneration characterized by ubiquitin-positive neuropathology (Hara et al. 2006, 
Komatsu et al. 2006). 
 
1.2.6 Regulation of autophagy by sphingolipids 
 
The regulation of the delicate balance between proliferation and cell death is another important 
aspect where sphingolipids act as second messengers. Specifically, S1P and ceramide have 
proved important in the regulation of cell fate (Scarlatti et al. 2004, Taniguchi et al. 2012), 
however, their effects on cell fate are very different (Le Stunff et al. 2002, Lavieu et al. 2006). 
Both acting through autophagy, S1P is believed to promote cell survival and proliferation, 
whereas ceramide has been found to induce growth arrest and cell death (Ogretmen et al. 2004). 
S1P has been found to upregulate autophagic activity under serum-starved conditions in PC-3 
prostate cancer cells. By applying small interfering RNA and dihydro-S1P, it was demonstrated 
that this process is regulated through S1P5-dependent pathways. In addition, mTOR signaling 
was inhibited upon exogenous S1P treatment (Chang et al. 2009). The role of S1P in autophagy 
regulation has been further investigated by manipulating its synthesis by sphingosine kinases 
(SK) or its degradation by S1P phosphatases (SPP) or S1P lyase (SPL). It has been shown that 
overexpression of SK1 in MCF-7 cells stimulates survival autophagy by increasing the formation 
of LC3-positive autophagosomes. In contrast to ceramide-induced autophagy in the same cell 
line, the SK1-induced autophagy proceeded independently of ceramide synthase activity, and was 
characterized by the inhibition of mTOR (independently of Akt/PKB signaling) and by the lack 
of Beclin 1 accumulation. Both SK1 activity and autophagy were enhanced upon nutrient 
starvation, resulting in cell protection from cell death and apoptotic features (Lavieu et al. 2006). 
In contrast, pharmacological inhibition of SK by dimethylsphingosine, the SK1 and SK2 dual 
inhibitor SK1-2 or the SK2- specific inhibitor ABC294640, resulted in increased autophagic 
features and death in A-489 kidney carcinoma cells (Beljanski et al. 2010). The autophagy 
induced by ABC294640 was associated with decreased levels of phospho-Akt and up-regulation 
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of Beclin 1, similar to the ceramide-induced autophagy described in Scarlatti et al.’s work 
(Scarlatti et al. 2004). However, the increased cytotoxicity observed in A-489 cells when 
combining SK inhibition and cytotoxics like sorafenib or gemcitabine was not due to enhanced 
autophagy, as there was no significant difference in the levels of LC3-II or Beclin 1 compared 
with cells treated with the individual compounds (Beljanski et al. 2011). 
Concerning S1P degradation, depletion of SPP1 has been reported to promote autophagy but 
without leading to autophagic cell death. This was mediated by ER stress, since downregulation 
of the expression of two major ER stress transducers, activating transcription factor 6 (ATF6) and 
inositol-requiring transmembrane kinase/endonuclease (IRE1a), completely abrogated SPP1-
regulated autophagy (Lepine et al. 2011). In this process, depletion of SPP1 induced Akt 
phosphorylation that protects cells from apoptosis; the class III PI3K/Beclin 1 complex and 
mTOR were not involved. Furthermore, it has been demonstrated that the autophagy induced by 
downregulation of SPP1 was mediated by intracellular S1P and not by secreted S1P, as treatment 
with exogenous S1P at concentrations that activate cell surface S1P receptors did not cause 
autophagy (Lepine et al. 2011).  
 
1.2.7 Behavioral phenotyping of mouse models of neurodegeneration 
 
Neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Huntington’s (HD), 
Parkinson’s (PD) and Alzheimer’s diseases (AD), are characterized by the loss of structure and 
function of specific neuronal circuitry in the brain. As a result of this loss, behavioral symptoms 
occur progressively. For understanding the causes of neurodegeneration several animal models of 
neurodegenerative disorders have been generated and characterized. Behavioral science plays a 
crucial role by identifying specific symptoms in these animal models of human disorders.  
Open-field test. The simplest tests of locomotor activity involve observing and recording an 
animal’s movements around an open arena. When placed in the center of a field, a mouse will 
typically run to the walled edge and then explore its way around the whole arena while remaining 
close to the wall. Over time, as the animal habituates to the new environment and its anxiety 
                                                                                                                  Introduction 
27 
 
reduces, the mouse will increasingly venture out towards central parts of the arena before 
returning to the edges. Exploitation of this behavioural profile forms the basis of the study of 
open-field locomotor activity test in mice (Brooks et al. 2009).  
In the object placement recognition test the mouse is placed in an enclosure where it is exposed 
to two objects for a defined time. The mouse is removed and later re-tested in the same 
environment, in which one of the two previously used objects has been moved in another part of 
the habitat. The time spent on exploring the object in the new location in the arena is recorded 
and reflects ability to remember what is new and what is old (Fig. 5 A) (Tuscher et al. 2015).  
The Morris water maze measures spatial reference memory. Mice are trained in a circular pool 
filled with an opaque liquid. Distant visual cues are provided for navigation around the pool. A 
platform is hidden just below the water surface. Mice swim until they find the platform. There are 
different ways to perform the test and also many parameters to assess memory, including path 
length and time to find the platform (escape latency). The test can be divided into two phases, an 
acquisition phase followed by a reversal phase during which the platform is moved to the 
opposite corner (Fig. 5 B) (Gotz et al. 2008). 
Contextual fear conditioning is the most basic of the conditioning procedures. It involves taking 
an animal and placing it in a novel environment, providing an aversive stimulus, and then 
removing it. When the animal is returned to the same environment, it generally will demonstrate 
a freezing response if it remembers and associates that environment with the aversive stimulus. 
Freezing is a species-specific response to fear, which has been defined as “absence of movement 
except for respiration.” This may last for seconds to minutes depending on the strength of the 
aversive stimulus, the number of presentations, and the degree of learning achieved by the subject 
(Fig. 5 C) (Curzon et al. 2009). 
Rotarod. The rotarod was specifically designed for making automated measurements of 
neurological deficits in rodents (Dunham et al. 1957), and is one of the most commonly used tests 
of motor function in mice (Fig. 5 D). Early designs use a rotating rod of ~3 cm diameter, on 
which the mouse is placed and has to maintain its balance; a trip switch on the floor below is set 
to record the latency until the mouse falls from the rotating rod. Mice are tested on separate trials 
at a series of fixed speeds, or speed increases can be incorporated into a single trial by using an 
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accelerating version of the test (Jones et al. 1968). In accelerating versions, the range of rod 
rotation speeds can differ markedly between studies, but typically revolutions of the rod 
accelerate smoothly from 0 to 40 rpm over a 5 minute period. The accelerating test is quicker and 
more efficient, but it confounds motor coordination at different speeds with fatigue, whereas the 
fixed-speeds test provides separate data on each range of rotation speeds and is probably more 
sensitive (Monville et al. 2006). The fixed-speeds test has been used to demonstrate that the age 
of onset of transgenic phenotypes is dependent on task difficulty and the sensitivity of the test to 
motor symptoms (Carter et al. 1999). There are several common confounds of the rotarod test. 
The first is that some animals may cling to the beam, and rotate with it, rather than fall when they 
lose balance. This is due to some commercial models having a rod that is grooved to aid grip, but 
to which the mice can cling by their claws; a simple solution is to cover the rod with a layer of 
coarse rubber. The second confound relates to individual animals that refuse the test and simply 
fall as soon as they are placed on the rod. This is especially relevant in longitudinal assessments, 
during which the animals can learn over repeated tests that the consequences of falling are 
innocuous. Fortunately these animals are relatively rare and their performance is conspicuous 
relative to that of the other mice in the cohort, thus they can be (and need to be) excluded as 
‘outliers’ in any statistical analysis. A third confound relates to mouse weight: heavy mice 
perform worse than light mice. Thus, genetic or lesion-induced weight loss can offset motor 
disability and potentially skew results. Finally, and particularly with the accelerating version of 
the rotarod, speed is confounded by fatigue at progressively longer latencies. However, 
demonstration of differential deficits at higher rotation rates in a series of fixed-speed tests 
(Carter et al. 1999) can be used to ensure that a more rapid fall is indeed attributable to problems 
with motor coordination rather than to greater susceptibility to fatigue. Despite these confounds, 
the rotarod remains one of the main tests of motor function in the mouse owing to its ease of use 
and sensitivity (Brooks et al. 2009). 
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Figure 5. Tests used to asses neurodegeneration in mice. A. Object palcement recognition (modified 
from (Tuscher et al. 2015)), B. Morris water maze (Gotz et al. 2008), C. Contextual fear conditioning 
(Curzon et al. 2009), D. Rotarod (Brooks et al. 2009). 
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1.3 Objectives of the study 
 
 
The bioactive lipid sphingosine 1-phosphate (S1P) is a component of the degradation pathway of 
sphingolipids that are particularly abundant in neurons. Its accumulation turned out to be 
neurotoxic leading to neuronal death (Hagen et al. 2009, Hagen et al. 2011). Alternatively, S1P is 
proposed as a neuroprotective factor that is lost early in Alzheimer pathogenesis (Couttas et al. 
2014). Mice with systemic deletion of SPL exhibit a quite severe phenotype and their life 
expectancy is limited to only 6-8 weeks (Hagen-Euteneuer et al. 2012). Therefore, a brain-
specific knockout mouse model of the enzyme responsible for irreversible S1P cleavage, S1P-
lyase (SPL), was generated. The aim of this study was to clarify the role of SPL, and respectively 
the accumulation of S1P in the brain.  
One of the objectives of the present study was to explore the impact of SPL knockout on the 
levels of brain lipids and hence on brain architecture and function. Note that earlier findings in 
primary cultured cerebellar neurons generated from mice with systemic SPL deletion resulted in a 
considerable accumulation of S1P and its metabolic precursor sphingosine with no changes in 
ceramide and sphingomyelin in brains of these mice  (Hagen-Euteneuer et al. 2012).  
In a recent study conducted in SPL-deficient MEFs an accumulation of APP most probably due 
to an impaired autophagy has been reported (Karaca et al., 29014). Thus another objective of the 
thesis was to investigate the involvement of SPL ablation in the autophagasom-lysosomal system 
and to uncover the molecular mechanism that could link SPL deficiency to neuronal autophagy. 
SPL links sphingolipid and phospholipid metabolism via its reaction product 
phosphoethanolamine (Fyrst et al. 2008). Of interest, phosphatidylethanolamine (PE) levels were 
shown to be decreased in neurodegeneration especially in brain regions highly affected by AD 
(Prasad et al. 1998). PE plays an important role in autophagosome formation and closure as it 
lipidates LC3-I. Thereby SPL activity might affect autophagy and hence essential physiological 
processes in the brain. 
 
 
 
 
32 
 
 
                                                                                                 Materials and Methods 
33 
 
2. MATERIALS AND METHODS 
 
2.1 Materials 
Antibodies. Monoclonal antibodies against synapsin-1, synaptophysin, PSD95, Bassoon, 
SNAP25, VAMP2, GFAP, beclin-1, LC3, p62, α-synuclein, IDE, Piccolo, NCS-1, GAP-43, 
Munc18, and ß-Actin (8H10D10), anti synaptotagmin1 polyclonal antibody, as secondary 
antibodies including HRP-linked anti-rabbit and anti-mouse IgG, and fluorescent secondary 
antibodies (anti-rabbit IgG (H+L), F(ab’)2 Fragment-Alexa Fluor 488 conjugated and anti-mouse 
IgG (H+L), F(ab’)2 Fragment-Alexa Fluor 555 conjugated) were from Cell Signaling Technology 
(Cambridge, UK). Anti-piccolo polyclonal serum was from Synaptic Systems (Göttingen, 
Germany), anti-syntaxin1a polyclonal antibody from Abcam (Cambridge, UK), anti-
ubiquitinylated proteins, clone FK2 (mouse monoclonal IgG1) from Millipore (Darmstadt, 
Germany), rabbit polyclonal anti USP14 was from Thermo Fisher (Rockford, IL, USA), Atg5 
(MBL Life Science (Nagoya, Japan), LAMP-2 (University of Iowa (Iowa City, IA, USA) 
Cathepsin D (kind gift of Prof. Dr. Stefan Hoening, Cologne. Polyclonal anti-APP C-terminal 
(Eurogentec (Liege, Belgium). 
Chemicals. PE, THI, Epoxomicin, Rapamycin and BAPTA-AM were purchased from Sigma-
Aldrich (Darmstadt, Germany) and MG-132 from Enzo Life Sciences (Loerrach, Germany). 
 
2.2 Mice 
All animal experiments were conducted in accordance with the guidelines of the Animal Care 
Committee of the University of Bonn and of the CBMSO/CAM.  
The Sgpl1flox/flox lines were generated as recently described. (Degagne et al. 2014) 
Sgpl1flox/flox mice, harbouring “floxed” exons 10-12 on both Sgpl1 alleles were crossbred with 
mice expressing nestin-Cre transgene. Thus SPLfl/fl/Nes mice in which “floxed” exons are excised 
by Cre recombinase were obtained.  
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2.3 Neuronal cultures  
Granular cells were cultured from the cerebella of 6-day-old mice as previously described. (van 
Echten-Deckert et al. 1997) Briefly, neurons were isolated by mild trypsinization (0.05%, w/v) 
and dissociated by passing them repeatedly through a constricted Pasteur pipette in a DNase 
solution (0.1%, w/v). The cells were then suspended in Dulbecco’s Modified Eagle’s Medium 
containing 10% heat-inactivated horse serum supplemented with 100 units/ml penicillin and 100 
mg/ml streptomycin and plated onto 15 mm sterile glass coverslips placed in 6-well plates, 35mm 
in diameter, and precoated overnight at 37° C with 0.01 mg/ml of Poly-L-Lysin dissolved in 1 x 
PBS (5 x 105 cells/well). 24 h after plating, cytosine-ß-D-arabinofuranosid hydrochloride (Sigma-
Aldrich, St. Louis, MO, USA) was added to the medium (4 x 10-5 M) to arrest the division of 
non-neuronal cells. After 10 days in culture cells were used for experiments as indicated.  
Primary cultures of hippocampal neurons were prepared from embryonic day 18 (E18) Wistar 
rats as described in Kaech and Banker. (Kaech et al. 2006)  Hippocampi were dissected and 
placed into ice-cold Hank's solution with 7 mM HEPES and 0.45% glucose. The tissue was then 
treated with 0.005% trypsin (trypsin 0.05% EDTA; (Invitrogen; Life Technologies Co.) and 
incubated at 37 °C for 16 min and then treated with DNase (72 μg ml−1; Sigma-Aldrich) for 1 min 
at 37 °C. Hippocampi were washed three times with Hank's solution. Cells were dissocia ted in 
5 ml of plating medium (Minimum Essential Medium supplemented with 10% horse serum and 
20% glucose) and cells were counted in a Neubauer Chamber. Cells were plated into dishes pre-
coated with poly-D-lysine (Sigma-Aldrich) (75.000 in a 3 cm dish for ICF and 150.000 in a 3 cm 
dish for WB) and placed into a humidified incubator containing 95% air and 5% CO2. The plating 
medium was replaced with equilibrated Neurobasal media supplemented with B27 and 
GlutaMAX (Gibco; Life Technologies Co.). On day in vitro (DIV) 7 the culture medium was 
replaced with medium without GlutaMAX. Cultures were used at 14 DIV. 
 
2.4 Organotypic adult brain slice cultures 
For hippocampal slice cultures 9 month old adult mice were used.  Coronal slices of 200 µm 
thickness were stored in artificial cerebrospinal fluid (ACSF) gassed with carbogen until 
cultivated. The slices were carefully placed onto sterile inserts with 8 µm pore size membrane 
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(Sarstedt 83.3930.800) in 6 well plates. Slices were kept 37 oC and 5% CO2 with 4 ml/well of the 
following culture medium: 50% MEM/HEPES (Gibco), 25% heat inactivated horse serum 
(Gibco/Lifetech, Austria), 25% Hanks’ solution (Gibco), 2 mM NaHCO3 (Merck, Austria), 
6.5 mg/ml glucose (Merck, Germany), 2 mM glutamine (Merck, Germany), pH 7.2 (Ullrich et al. 
2011). Slices were incubated for 24 h with and without PE and processed further for Western 
Blotting. 
 
2.5 Lipid extraction and quantification  
Lipid measurements were performed according to an established protocol using liquid 
chromatography coupled to triple-quadrupole mass spectrometry (LC/MS/MS) (Bode et al. 
2012). Tissue samples were homogenized using the Stomacher Model 80 MicroBiomaster 
Blender (Seward) in 5 ml PBS after addition of C17-base sphingosine (Sph) and C15-base 
ceramide (Cer) as internal standards (300 pmol/sample, Avanti Polar Lipids). One ml 
supernatants were transferred into glass centrifuge tubes and mixed with 200 μl of 6 N 
hydrochloric acid and 1 ml methanol, and vigorously vortexted for 5 min in the presence of 2 ml 
chloroform. Aqueous and chloroform phases were separated by centrifugation for 3 min at 1900 x 
g, and the lower chloroform phase was transferred into a new glass centrifuge tube. After a 
second round of lipid extraction with additional 2 ml chloroform, the two chloroform phases were 
combined and vacuum-dried at 50 °C for 50 min using a vacuum concentrator. The extracted 
lipids were dissolved in 100 μl methanol/chloroform (4:1, v/v) and stored at -20 °C. Detection 
was performed with the QTrap triple-quadrupole mass spectrometer (ABSciex, Concord, Canada) 
interfaced with the 1100 series chromatograph (Agilent, Santa Clara, California, USA), the 
Hitachi Elite LaChrom column oven (VWR, Radnor, Pennsylvania, USA), and the Spectra 
System AS3500 autosampler (Thermo Separation Products). Positive electrospray ionization 
(ESI) LC/MS/MS analysis was used for detection of sphingosine 1-phosphate (S1P), Sph, 
sphingomyeline (SM), and phosphatidylcholine (PC), positive atmospheric pressure chemical 
ionization (APCI) for detection of Cer, hexosylcerebrosides (GalCerBr), and cholesterol (Chol), 
and negative ESI for detection of phosphatidylethanolamine (PE). Multiple reaction monitoring 
(MRM) transitions were as follows: S1P m/z 380/264, C17-S1P m/z 366/250, C17-Sph m/z 
286/268, C15-Cer m/z 524/264 (positive mode) 522/266 (negative mode), C16-Cer m/z 538/264, 
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C18-Cer m/z 566/264, CerBr (24:1) m/z 810/264, SM (16:0) m/z 703/184, SM (18:0) 731/184, 
PC (34:1) m/z 760/184, PC (34:2) m/z 758/184 PE (36:2) m/z 742/281; PE plasmalogen (36:2) 
m/z 728/281, Chol m/z 369/161. Liquid chromatographic resolution of all analytes was achieved 
using a 2 x 60 mm MultoHigh C18 reversed phase column with 3 μm particle size (CS-
Chromatographie Service). The column was equilibrated with 10% methanol and 90% of 1% 
formic acid in H2O for 5 min, followed by sample injection and 15 min elution with 100% 
methanol with a flow rate of 300 μl/min. Standard curves were generated by adding increasing 
concentrations of the analytes to 300 pmol of the internal standard. Linearity of the standard 
curves and correlation coefficients were obtained by linear regression analyzes. Data analyzes 
were performed using Analyst 1.6 (ABSciex, Concord, Canada). 
 
2.6 Reverse transcription and real-time PCR 
Total RNA was extracted from brains using RNeasy Mini Kit (QIAGEN, Hilden, Germany), and 
treated with RNase-free DNase (QIAGEN) according to the manufacturer’s instructions. Reverse 
transcription of 1 µg of total RNA was performed using the First Strand cDNA Synthesis Kit 
(ProtoScript II, New England BioLabs, Frankfurt am Main, Germany). The primers for real-time 
PCR were designed using the online tool from Life Technologies „Custom Primers - 
OligoPerfect™ Designer” and obtained from the same company. They are listed as follows: 
name: forward primer, reverse primer: bassoon: 5’TACACCGCTCTTCCTGCTCT3’, 
5’TGTACTCGCTGCCAGACTTG3’; synapsin-1: 5’TCCAGAAGATTGGGCAGAAC3’, 
5’TCAGACATGGCAATCTGCTC3’; synaptophysin: 5’AGTACCCATTCAGGCTGCAC3’, 
5’CCGAGGAGGAGTAGTCACCA3’; syntaxin 1: 5’GAACAAAGTTCGCTCCAAGC3’, 
5’ATTCCTCACTGGTCGTGGTC3’; vamp2: 5’TGACGGTTCCCATCACCTCTC3’, 
5’CTGTGGGGTTTGCTTTTGTT3’; psd-95: 5’TTTCTCCCACACACATTCCA3’, 
5’ACCTTCCACTCATGCAAACC3’; s1p-lyase: 5’TTTCCTCATGGTGTGATGGA3’, 
5’CCCCAGACAAGCATCCAC3’; β-actin: 5’CCACAGCTGAGAGGGAAATC3’, 
5’TCTCCAGGGAGGAAGAGGAT3’; 12.5 µl of Power SyBR Green (Applied Biosystems, 
Carlsbad, California, USA), 2 µl of each primer, 1.5 µl of cDNA, and 9 µl of H2O were loaded 
into a 96 well plate and PCR performed in a 7300 Real Time PCR System (Applied Biosystems, 
Carlsbad, California, USA). Results were calculated using the relative CT method. The fold 
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increase or decrease was determined relative to controls after normalizing to β-actin as 
housekeeping gene. 
 
2.7 Western blotting and immunoprecipitation 
Total brains, hippocampi or cultured neurons were homogenized twice for 2 min using metallic 
beads at a frequency of 20 Hz in RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% NP-40, 1% NaDC, 2.5 mM Na4P2O7, 1 mM b-glycerophosphate, 1 mM 
Na3VO4, 1 µg/ml leupeptin). Samples were kept on ice for 1 h followed by centrifugation at 
13,000 rpm at 4°C for 1 h. The protein concentration of the supernatants was determined using 
the Pierce BCA protein assay kit (Thermo Scientific, Waltham, MA). Samples were stored at -
20°C until use.  
Proteins were immunoprecipitated from cleared lysates using primary antibodies (5 µg/ml) and 
protein G-conjugated sepharose (GE Healthcare, Little Chalfont, UK) for 3 hrs at 4°C. 
Precipitates were rinsed three times with washing buffer (50 mM Tris/HCl, pH 7.4, 500 mM 
NaCl, 2 mM EDTA, 0.2% Igepal) for 10 min at 4°C. Precipitates were collected by 
centrifugation (4,000× g, 4°C, 5 min) and eluted by incubation with SDS sample buffer (25 mM 
Tris/HCl, pH 6,8, 10% Glycerin, 1,5% SDS, 20 mM DTT) for 10 min at 95°C. Lysates from total 
brain and cell cultures were incubated with SDS sample buffer for 10 min at 95°C. 
Proteins were separated by SDS-PAGE in running buffer (25 mM Tris, 192 mM glycine, 0.1% 
SDS) at 200 V. Transfer onto nitrocellulose membranes (Porablot NCL, Macherey-Nagel, Düren, 
Germany) was carried out at 4°C and 300 mA for 2 h in blotting buffer (50 mM Tris, 40 mM 
glycine, 0.03% SDS, 20% methanol). Membranes were blocked with 5% milk powder in TBS-
Tween20 for 1 h, washed and incubated at 4°C overnight with the primary antibody. Then 
membranes were washed three times for 10 min and incubated for 1 h with an HRP-conjugated 
secondary antibody. Western Lightning Plus ECL (PerkinElmer, Waltham, MA) was used for 
detection, VersaDoc 5000 imaging system (Bio-Rad, Hercules, CA) for visualizing the 
membranes, and ImageJ program for quantification. 
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2.8 Electron microscopy 
Mice were intracardially perfused with PBS and fixative (4% PFA and 2% glutaraldehyde in 
PBS). Brains were fixed in 4% PFA overnight and sectioned in 200-µm-thick slices. 
Hippocampal sections were postfixed in 1% osmium tetroxide (in 0.1 M cacodylate buffer), 
dehydrated in ethanol and embedded in Epon. Serial ultrathin sections of the CA1 region were 
collected on pioloform-coated, single-hole grids, and stained with uranyl acetate and lead citrate. 
The sections were examined with a transmission electron microscope (JEM1010, jeol, Akishima, 
Tokyo, Japan). CA1 neurons identified by position were sampled randomly and photographed at 
a magnification of x 8.000 with a CMOS 4 k TemCam-F416 camera (TVIPS, Gauting, 
Germany). The number of autophagic structures and lysosomes was quantified using ImageJ 
software (National Institute of Health, Bethesda, MD, USA) in 10 randomly selected CA1 
neurons from three mice per genotype and age. The area of each cell was also calculated and the 
values of autophagic structures and lysosomes /µm2 were statistically compared.  
 
2.9 Immunocytochemistry 
Coverslips with cerebellar neurons were washed with phosphate-buffered saline (PBS) and then 
fixed with 4% paraformaldehyde for 10 min. Then cells were permeabilized with 0.25% Triton-
X100-PBS for another 10 min and blocked with 5% BSA in 0.125% Triton X-100 in PBS for 1h. 
After blocking cells were incubated for 1h with the primary antibody diluted in 2.5% BSA in 
0.125% Triton X-100 in PBS. Following washing with 0.125% Triton X-100 in PBS, cells were 
incubated with a mixture of secondary antibodies conjugated to Alexa Fluor 488, and Alexa Fluor 
647 Phalloidin (1:20 in PBS) (for F-actin staining), and DAPI (1:1000 in PBS) for another hour. 
Reagents were obtained from Cell Signaling Technology (Cambridge, UK). After washing, 
coverslips were mounted on glass slides and stored at 4oC in the dark until analysis. The slides 
were imaged using an LSM 710 Axio Observer confocal laser scanning microscope (Carl Zeiss, 
Oberkochen, Germany). 
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2.10 Immunohistofluorescence 
Mice were intracardially perfused with phosphate buffer saline (PBS) and 4% paraformaldehyde 
(PFA), fixed with 4% PFA in PBS overnight at 4oC and then cryoprotected in 30% sucrose in 
PBS for 48 h. Next, samples were frozen in Optimal Cutting Temperature (Tissue-Tek). Sagittal 
sections (30 µm) were obtained with a CM 1950 Ag Protect freezing microtome (Leica, Solms, 
Germany). Sections were incubated with the primary antibody 72 hours at 4oC in a PB 0.1 N 
solution containing 1% bovine serum albumin and 1% Triton X-100. After washing with 
blocking solution, sections were incubated with donkey Alexa-conjugated secondary antibody 
overnight at 4oC (Molecular Probes, Eugene, OR, USA and Millipore, Billerica, MA, USA). 
Finally, sections were washed and mounted with Prolong Gold Antifade (Invitrogen).  Images 
were taken with a confocal LSM710 META microscope (Carl Zeiss AG). 
 
2.11 Proteasomal activity  
Proteasomal activity was assessed using the Proteasome Activity Fluorometric Assay Kit, 
(BioVison, CA, USA). Proteasomal inhibitors epoxomycin and MG-132 were from Merck-
Millipore (Darmstadt, Germany) and from Enzo Life Sciences (Loerrach, Germany), 
respectively. 
 
2.12 THI and PE treatment in cultured neurons 
SPL activity was modulated in 14DIV cultured hippocampal neurons from wt rats by addition for 
3 hours (h) of 100 µM THI (SPL inhibitor) (Sigma-Aldrich), which was added from a stock 
prepared in DMSO. For rescue experiments with PE wt neurons were incubated for 3 h with 100 
µM THI and 10 µM PE (Sigma-Aldrich). PE was added from a stock prepared in ethanol that 
ensured a final ethanol concentration of less than 1 % in the neuronal medium to avoid toxicity.  
Same amounts of DMSO or/and ethanol were added to control neuronal cultures. 
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2.13 mRFP-EGFP tandem fluorescent-tagged LC3 expression 
Primary hippocampal neurons and cerebellar neurons were transfected with mRFP-GFP tandem 
fluorescent-tagged LC3 (Kimura et al. 2007) using Lipofectamine 2000 reagent (Invitrogen) on 
DIV 11. After 72 h, hippocampal neurons were treated with 100 µM THI or with 100 µM THI 
and 10 µM PE for 3 h. Finally neurons were fixed with 4 % PFA for 10 min, stained with DAPI 
(1/5000; Calbiochem) and analyzed in a confocal LSM710 META microscope (Carl Zeiss AG). 
The number of RFP-positive structures were quantified with respect to the total number of 
structures EGFP and RFP-positive per cell. 
 
2.14 Behavioral Analysis 
To habituate animals to the investigator, they were handled for 3 days (for approximately 2 
min/animal/day) before the onset of behavioral testing. Before the onset of behavioral testing 
animals were kept for at least 30 min the test room to accommodate to the environment. Between 
trials used issues were cleaned with terralin to remove odor cues.  
Open field. The test apparatus (ActiMot; TSE) was a transparent and infrared light–permeable 
acrylic test box (45.5 cm × 45.5 cm × 39.5 cm internal measurements). Animals were allowed to 
freely explore the test arena for 20 minutes. An automated tracking system (Ethovision XT; 
Noldus) was used to record the total distance traveled by animals. 
Object placement recognition. After handling and habituation to the empty test arena, mice were 
subjected to 3 trials of 6-minute training session, during which they were allowed to explore 
freely 2 identical objects (small glass bottles) that were placed in defined locations of the test 
arena. Next day, a 6-minute test session was performed, during which the position of one of the 
objects was changed, while the position of the other remained unaltered. An automated tracking 
system (Ethovision XT; Noldus) was used to monitor and record the behavior of the animals. The 
time the animals spent exploring the object in the novel location and the known location during 
the test was hand-scored by an observer from the videotape by an observer blinded to the 
experimental conditions.  
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Rotarod. An accelerating rotarod (Bioseb, Vitrolles, France) was used to measure motor 
coordination, balance, and motor learning abilities (Jones et al. 1968). Mice were placed on the 
rotarod, and the rod rotations were subsequently accelerated from 4 to 40 rpm during the 5-
minute trial period. Trials were terminated when animals fell off the rod or when 5 minutes had 
elapsed, whichever came first. Mice were given 3 trials every day with a 30 min intertrial 
interval, for 4 consecutive days.  
Hidden version of the Morris water maze. The water maze was performed essentially as 
previously described (Heinen M1 2012). Each animal received 6 daily training trials in the hidden 
version of the Morris water maze (in blocks of 2 consecutive trials) for 7 consecutive days. 
Training trials were completed when mice climbed on the escape platform or when 1 minute had 
elapsed, whichever came first. To evaluate the accuracy with which the animals had learned the 
position of the escape platform, we performed a probe trial after completion of training on day 3, 
5, and 7. We determined the time that mice spent searching in the target quadrant (which 
previously contained the escape platform) or the other quadrants during the probe trial. 
Additionally, we analyzed the number of crossings of the exact target location (i.e., where the 
platform was during training) and compared it with crossings of analogous positions in the other 
quadrants. 
Context fear conditioning. A near infrared video fear conditioning system (Med Associates, 
Vermont, USA) was used to test context fear conditioning. The training session was 306 seconds 
total duration; 2-second, 0.75-mA shocks were delivered via the metal grid floor of the chambers 
after 120, 182 and 244 seconds. A single test session was given on the next day, during which 
animals were placed in the chamber for 300 seconds to record behavior. Time freezing and 
average motion were calculated with the Video Freeze® software (Med Associates). To evaluate 
conditioned fear, we calculated the freezing time on the test day and activity suppression ratios 
for each animal as activity during test/activity during test + activity during baseline. 
 
2.15 Statistical analysis  
All values are presented as means ± SEM. Student’s t-test and two-way ANOVA were used for 
statistical analysis of the data. P values lower than 0.05 were considered significant. In the figures 
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asterisks indicate P values as follows: * < 0.05; ** < 0.01; *** < 0.001. The GraphPad Prism 5 
software was used for statistical analysis.  
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3. RESULTS  
 
3.1 Generation of a brain-specific SPL knockout mouse model  
Mice in which exons 8/9 and 12/13 encoding for the binding site of the SPL cofactor 
pyridoxalphosphate (PLP) were flanked by loxP sites (floxed, Sgpl1 flox/flox) were crossbred with 
the nestin-Cre transgenic mouse line Nes-Cre1 in which Cre-recombinase expression is under the 
control of the nestin promoter (Dubois et al. 2006). Siblings expressing both, loxP sites and Cre-
recombinase (SPLfl/fl/Nes) exhibited a reduction of about 90 % of SPL in the brain on 
transcriptional and protein level (Fig. 1 A, B). The residual mRNA amounting to 10 ± 4% is most 
probably derived from non-neural cells devoid of an active  nestin promoter (Dubois et al. 2006). 
Accordingly, a slight protein band was also detectable (Fig. 1 B). In contrast to systemic SPL 
deletion, mice lacking SPL only in neural tissue (SPLfl/fl/Nes) have no eye-catching phenotype and 
their lifespan is comparable to that of their wild type littermates, thus representing a promising 
model to analyze the role of SPL in brain physiology.  
 
3.2 SPL ablation causes sphingosine and S1P accumulation and PE reduction in brains of 
SPLfl/fl/Nes mice 
SPL catalyzes  the final step in the sphingolipid degradative pathway and is an important 
regulator of cellular S1P (Fyrst et al. 2008). Thus SPL on the one hand reduces S1P levels and on 
the other hand generates hexadecenal and ethanolamine phosphate  (Serra et al. 2010). Consistent 
with earlier findings in primary cultured cerebellar neurons generated from mice with systemic 
SPL deletion (Hagen-Euteneuer et al. 2012), neural-targeted depletion of SPL resulted in a 
considerable accumulation of S1P (Fig. 1 C) and its metabolic precursor sphingosine  (Fig. 1 D) 
with no changes in ceramide (not shown) and sphingomyelin (Fig. 1 E) in brains of SPLfl/fl/Nes 
mice. 
Ethanolamine phosphate, one of the products of SPL, is used as a biosynthetic precursor for PE 
formation (Fyrst et al. 2008). It was therefore not surprising that the content of PE was reduced in 
brains lacking SPL activity (Fig. 1 F).  The reduction of PE levels in both hippocampus and 
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cerebellum of SPLfl/fl/Nes mice was significant at all ages studied (3, 9 and 12 month-old) 
excluding the weaning period at which no changes between controls and SPL-deficient mice 
could be detected (Fig. 1 F).  
 
 
Figure 1. Brain targeted  knock-down of SPL and its impact on sphingolipid and phospholipid content. 
SPL expression was assessed in the indicated brain domains of 6 week old mice of the indicated genotype 
by A, qRT-PCR (unpaired t test, P < 0.0001 ), B, Western blotting as described in the Methods section. C-
E, Sphingolipids from the cerebellum and the hippocampus of mice at the indicated age and genotype 
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were determined by LC/MS/MS as described in the Methods section. Sphingosine 1-phosphate (S1P) and 
sphingosine (Sph) increased considerably already after 6 weeks in brains of SPLfl/fl/Nes. Bars represent 
means ± SEM (n ≥ 3; two -way ANOVA, PS1P,h6w = 0.041, PS1P,h12m = 0.0458, PS1P,c6w = 0.041, PS1P,c12m = 
0.0458,PSph,h6w =0.0326, PSph,h12m =0.0284, PSph,c6w =0.0326, PSph,c12m =0.0284). F, Means ± SEM values of 
PE levels quantified in pmol/mg tissue by LC/MS/MS in the hippocampus and cerebellum of control and 
SPLfl/fl/Nes mice at the indicated ages (n ≥ 3; two-way ANOVA, Ph3m = 0.041, Ph9m = 0.0458, Ph12m =0.0326, 
Pc3m =0.0284, Ph9m = 0.0474, Ph12m =0.0471). The amount of all other lipids determined including 
ceramides did not change upon SPL  
 
3.2.1 Increase in GPBP, a longer isoform of CERT, in the brain of SPLfl/fl/Nes mice.  
Ceramide, sphingosine and S1P are metabolic interconnected (Gault et al. 2010). The 
accumulation of sphingolipids that are directly involved in the reaction catalyzed by SPL and the 
normal levels of more complex sphingolipids like ceramide made us wonder whether ceramides 
might be transported extracellular keeping the regular level of ceramide. The GPBP (Goodpasture 
antigen-binding protein) and its splice variant the CERT (ceramide transporter) are 
multifunctional proteins that have been found to play important roles in brain development and 
biology, and mediates ceramide trafficking (Hanada et al. 2003). Mencarelli et al. suggest that 
GPBP may be able to transport ceramide to the extracellular space (Mencarelli et al. 2010). 
Therefore we investigated a possible involvement of GPBP and indeed, we saw an increase in its 
mRNA level (Fig.2). 
 
Figure 2. Up-regulation of Gpbp (a larger splicing variant of Cert) mRNA in SPLfl/fl/Nes mice. Real time analysis 
of Gpbp in the brain (n ≥ 3; two-way ANOVA, P3m = 0.0365, P12m = 0.0483). 
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3.3 SPL deficiency triggers accumulation of aggregate prone proteins in the brain   
SPL ablation was shown to affect APP processing in MEFs (Karaca et al. 2014). Cells lacking 
functional SPL strongly accumulate full-length APP and it’s potentially amyloidogenic C-
terminal fragments (CTFs) as compared to cells expressing the functional enzyme (Karaca et al. 
2014). Likewise, enhanced levels of both, full-length APP (APP-FL) and of APP-C-terminal 
fragment (CTFs) were detected in the brains of SPLfl/fl/Nes mice compared to controls (Fig. 3 A). 
We also found accumulation of α-synuclein in SPL-deficient brains (Fig. 3 B). The accumulation 
of APP-FL and of α-synuclein was already evident at early stages (3 months of age) and was 
maintained at all ages analysed. Moreover, we could see an increase in phospho-tau and total tau 
(Fig. 3 C, D).  
 
Figure 3. Accumulation of aggregate prone proteins in SPL-deficient brains. Representative Western 
blot images and graphs showing mean ± SEM in brain extracts of control and SPLfl/fl/Nes mice of the 
indicated ages for: A, APP-FL (full length) and APP-CTFs (C-terminal fragments) (n ≥ 3; two -way 
ANOVA, Pgenotype, APP-FL = 0.0034, Ptime,APP-CTFs = 0.0453, Pgenotype,APP-CTFs = 0.0359). B, α-synuclein (n ≥ 3; 
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two-way ANOVA, Pgenotype = 0.0050). C, Western blot analysis of phosphorylated tau (unpaired t test, P = 
0.0476) and  D, total tau in the 12-month-old mice (unpaired t test, P = 0.0483). 
 
3.3.1 Autophagy alterations in the brains of SPLfl/fl/Nes mice 
Impairment of autophagy has been implicated in the pathogenesis of neurodegenerative disorders 
by contributing to the accumulation of aggregate prone proteins (Komatsu et al. 2006). This is the 
case of APP derived amyloidβ, α-synuclein and of tau protein, which play critical roles in the 
pathogenesis of AD, Parkinson’s disease (PD) and taupathies (Recchia et al. 2004). 
There is convincing experimental evidence for the essential role of PE in the regulation of 
autophagy. (Rockenfeller et al. 2015) Therefore, we investigated whether and how autophagy is 
affected in brains with neural targeted SPL deletion. First, levels of different autophagic markers 
were assessed in control and SPLfl/fl/Nes mice brains at different ages. We found increased 
expression of beclin-1, which is involved in the initiation of autophagosome formation, thus 
suggesting an elevation of autophagic activity (Fig. 4 A). However, the conversion of LC3-I into 
LC3-II was considerably hampered in the absence of SPL activity suggesting an impairment of 
the autophagic flux (Fig. 4 B). Accordingly, the specific autophagic substrate p62 was 
significantly increased in SPLfl/fl/Nes brains (Fig. 4 C).  Electron microscopy analysis in the 
hippocampus of control and SPLfl/fl/Nes mice of different ages indicated an early (already evident 
at 3 months of age) and significant decrease of autophagolysosome-like structures in SPL-
deficient neurons (Fig. 5 A). These were characterized by electron dense material inside vacuoles 
of heterogeneous size engulfed by a double membrane. In contrast, the number of phagophore-
like structures consisting of curved but unclosed double membranes was increased upon SPL 
deficiency (Fig. 5 A). These data suggested a block in autophagosome formation. To further 
analyze this point we performed immunofluorescence analysis of LC3 in hippocampal tissue. 
LC3 staining in control mice showed a preferential punctate distribution consistent with the 
incorporation of the protein in autophagosomes as LC3-II (Fig. 5 B). In contrast, LC3 staining in 
the hippocampus of SPLfl/fl/Nes mice showed a diffuse, less punctated, pattern (Fig. 5 B). This 
supports the enhanced presence of LC3 in the cytosol as LC3-I and is consistent with the reduced 
LC3-II/LC3-I ratio evidenced by Western blot (Fig. 4 B).  
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Figure 4. Autophagy is altered in SPL-deficient brains. A, B, C, Western blots and graphs showing 
mean ± SEM in brain extracts from control and SPLfl/fl/Nes mice for: A, Beclin-1 at the indicated ages (n ≥ 
3; two-way ANOVA, Pgenotype = 0.0004), B, LC3-I and LC3-II at 12 months of age (n ≥ 3; unpaired 
Student’s t test, PLC3 = 0.0025) and C, p62 at 12 months of age (n ≥ 3; unpaired Student’s t test, Pp62 = 
0.0412).  
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Figure 5. Autophagy morphology is changed in SPL-deficient brains. A, Electron micrographs from 
CA1 hippocampal neurons of control and SPLfl/fl/Nes mice showing autophagolysosome-like structures 
(AL), lysosomes (L), and phagophore-like structures (P) (unpaired Student’s t test, PAL,3m = 0.0177 PP,3m = 
0.0031, PAL,12m = 0.0021, PL,12m < 0.0001, PP,12m =0.0115). B, Representative images of 
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immunofluorescence analysis of the CA1 hippocampal brain region in control and SPLfl/fl/Nes mice of 3 or 
12 months of age using the anti-LC3 antibody.  
 
3.3.2 Lysosomal up-regulation in the brain of SPLfl/fl/Nes mice 
Autophagy is intimately connected with lysosomal degradation. Thus, fusion of autophagosomes 
and lysosomes constitutes the final step of cargo degradation in the autophagic pathway.  To 
assess whether lysosomal alterations exist upon SPL deficiency we first analysed these organelles 
by electron microscopy. This analysis revealed an increase in lysosome number in the 
hippocampus of SPLfl/fl/Nes mice compared to control mice that was especially significant at 12 
month of age (Fig. 5 D). Biochemical analysis also showed a considerably elevated expression of 
the lysosome-associated membrane protein-2 (LAMP-2) in brains of SPLfl/fl/Nes mice, which was 
evident already at 3 months of age and was sustained along aging (Fig. 6 A). We next analysed 
the expression of the lysosomal protease cathepsin D (Bankowska et al. 1997). Both, the 
intermediate and active forms of this protease were significantly increased in SPLfl/fl/Nes mice at 
all ages (Fig. 6 B). However, the ratio active/intermediate form of cathepsin D reveals an 
absolute increase of active cathepsin in SPLfl/fl/Nes mice brains only in the oldest mice (12 months) 
analysed.  
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Figure 6. Up-regulation of lysosomal markers in SPL-deficient brains. Representative Western blot 
images and graphs showing mean ± SEM in brain extracts  from control and SPLfl/fl/Nes mice for: A, 
LAMP-2 (n ≥ 3; two-way ANOVA, P3m = 0.0197, P9m = 0.013, P12m = 0.0481) and B, Cathepsin D (with 
indication of intermediate and active variants) (n ≥ 3; two-way ANOVA, total Cathepsin D, Ptime = 0.0497, 
Pgenotype < 0.0001, and Cathepsin D active/intermediate, P12m = 0.0455).  
 
3.3.3 Autophagic flux is blocked at initial stages upon SPL deficiency 
The biochemical analysis showing diminished LC3-II/LC3-I ratio but increased levels of Beclin-
1 and p62 in SPL deficient mouse brains, together with reduced autophagolysosome-like but 
increased phagophore-like structures detected by electron microscopy (Fig. 4, 5), suggested a 
blockage in the autophagic flux at the initial stages. To gain further insight on autophagy flux we 
moved to the in vitro analysis in neuronal cultures from control and SPLfl/fl/Nes mice in which we 
expressed the EGFP-mRFP-LC3 construct. This tandem fluorescent-tagged autophagosomal 
marker in which LC3 was engineered with both red-fluorescent protein (mRFP) and green-
fluorescent protein (EGFP) allows the labelling of autophagosomes in yellow (merged green 
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EGFP and red mRFP fluorescences), whereas autophagolysosomes appear red only as 
acidification after autophagosome–lysosome fusion quenches EGFP fluorescence (Kimura et al. 
2007). Quantification of autophagolysosomes (red only structures) revealed a significant 
reduction in SPL-deficient neurons compared to controls (Fig. 7 A). We also employed a parallel 
approach in neurons in which SPL had been pharmacologically inhibited. THI was previosly 
known not to inhibit SPL in vitro either in cell-free or cell-based systems. A reason of this was 
that the in vitro experimental conditions were not suitable for the evaluation of SPL inhibition 
(Ohtoyo et al. 2015). A key factor might be the coenzyme pyridoxal 5’-phosphate (PLP), which 
is an active form of vitamin B6 that can be found in excess in culture media leading to the 
activation of SPL (Ohtoyo et al. 2015). Consistent with the observations made in the brains of 
SPLfl/fl/Nes mice, the treatment of 14 days in vitro hippocampal neurons from wild-type (wt) rats 
with the SPL inhibitor THI resulted in higher expression levels of the autophagy initiation protein 
Atg5-Atg12 and in diminished LC3-II/LC3-I ratio (Fig. 7 B). We next expressed the construct 
EGFP-mRFP-LC3 in wt cultured hippocampal neurons in which SPL was pharmacologically 
inhibited with THI and observed a significant reduction of autophagolysosomes in THI treated 
compared to non-treated cultured neurons (Fig. 7 C). These results are consistent with SPL 
inhibition blocking autophagic flux at early stages thus preventing the fusion of autophagosomes 
and lysosomes. 
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Figure 7. Genetic and pharmacological inhibition of SPL impairs autophagy flux in cultured 
neurons.  A, C, Images showing the fluorescence associated to mRFP-EGFP-LC3 construct 
expressed in cultured neurons from SPLfl/fl/Nes and control mice (A) (unpaired Student’s t test, P < 
0.0001) and in cultured hippocampal neurons from wt rats treated or not with THI (C) (unpaired 
Student’s t test, P < 0.0001). DAPI staining indicates cell nuclei in blue. Graph shows mean ± 
SEM of the percentage of red structures corresponding to autophagolysosomes with respect to the 
total number of structures (red and yellow) per cell (n=20 cells in each of two different cultures) 
B, Representative Western blot images and graphs showing mean ± SEM in extracts from 
cultured hippocampal neurons from wt rats treated or not with THI for the ATG5-ATG12 
complex (unpaired Student’s t test, P = 0.0067) and for LC3 (unpaired Student’s t test, P = 
0.0063). 
 
3.3.4 PE restores autophagic flux and control levels of p62, APP and α-synuclein in cultured 
neurons with pharmacological or genetic inhibition of SPL 
We showed above that ablation of SPL decreases the levels of PE in the brain.  Since PE is 
essential for the conversion of LC3-I into LC3-II, and thus for autophagosome formation, we 
checked whether this lipid was able to rescue autophagic flux in SPL-deficient neurons. As 
depicted in Figure 8 A addition of PE to cultured neurons derived from SPLfl/fl/Nes mice indeed 
restored the conversion of LC3-I into LC3-II and the amount of p62 to control levels. This was 
also the case in cultured neurons derived from wt rats treated with THI and PE (Fig. 8 B). In 
addition, PE supplementation reestablished the autophagy flux in EGFP-mRFP-LC3 expressing 
wt neurons in which SPL was pharmacologically inhibited by THI as evidenced by the enhanced 
number of red structures corresponding to autophagolysosomes (Fig. 8 C). Finally, PE addition 
prevented the accumulation of APP and of α-synuclein levels in cultured neurons from SPLfl/fl/Nes 
mice as determined by Western blot (Fig. 8 D).  
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Figure 8. PE restores autophagic flux and prevents accumulation of APP and α-synuclein in SPL-
deficient neurons. A, Representative Western blot images for LC3 and p62 and graphs showing mean ± 
SEM in extracts from cultured neurons treated or not with PE  from: A, control and SPLfl/fl/Nes mice (n ≥ 3; 
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two-way ANOVA, PLC3,genotype = 0.0072, PLC3,treatment = 0.0293, Pp62,genotype = 0.0001, Pp62,treatment = 0.0158); B,  
wt rats none treated (control), or treated with THI in the absence or presence of PE (n ≥ 3; one -way 
ANOVA, PLC3,THI = 0.0005, PLC3,THI+PE = 0.0056, Pp62,THI = 0.0112, Pp62,THI+PE = 0.0113). C, Images showing 
the fluorescence associated to mRFP-EGFP-LC3 construct expressed in cultured neurons from wt rats 
none treated (control) or treated with THI in the absence or presence of PE. DAPI staining indicates cell 
nuclei in blue. Graph shows mean value ± SEM of the percentage of red structures corresponding to 
autophagolysosomes with respect to the total number of structures (red and yellow) per cell (n=20 cells in 
each of two different cultures) (one-way ANOVA, PTHI < 0.0001, PTHI+PE < 0.0001). D, Representative 
Western blot images for APP and α-synuclein and graphs showing means ± SEM values in extracts from 
cultured neurons from control and SPLfl/fl/Nes mice treated or not with PE (n ≥ 3; one-way ANOVA, PAPP = 
0.0304, Psyn = 0.0204). 
 
3.3.4.1 PE restores control levels of p62 and LC3 in adult hippocampal slice cultures from 
SPLfl/fl/Nes mice 
In vitro cell culture models are important in neuroscience research, but organotypic brain slices 
are found to be a potent model very close to the in vivo situation. Therefore, we prepared 
hippocampal slices and we incubated them with PE. The same results like in the neuronal 
cultures were obtained. PE could re-establish SQSTM1/p62 and LC3 to control levels in the 
SPLfl/fl/Nes slices (Fig. 9).  
 
Figure 9. Ex vivo PE treatment of hippocampal slices re-establish autophagic markers in SPLfl/fl/Nes 
mice.  Representative Western blot images for SQSTM1/p62 and LC3, and graphs showing mean ± SEM 
                                                                                                                          Results 
57 
 
in extracts from hippocampal slice cultures treated or not with PE  from control and SPLfl/fl/Nes mice (n ≥ 3; 
two-way ANOVA, Pp62,genotype = 0.0041, Pp62,treatment = 0.0227, PLC3,genotype = 0.0031, PLC3,treatment = 0.0446). 
 
3.3.5 Impaired autophagy in SPL-deficient neurons is mTOR independent  
Nutrient starvation induces autophagy in eukaryotic cells through inhibition of mTOR 
(mammalian target of rapamycin) protein kinase (Jung et al. 2010). Rapamycin binds to a domain 
separate from the catalytic site to block a subset of mTOR functions (Ballou et al. 2008). We 
observed that the treatment of Rapamycin has no effect on the neuronal cultures from SPL fl/fl/Nes 
mice, although in the neuronal cultures form control mice we could see an increase in autophagy 
illustrated by the increase in LC3 and decrease of SQSTM1/p62 levels (Fig. 10). 
 
Figure 10. Rapamicyn stimulated autophagy could not save impaired autophagy in SPLfl/fl/Nes 
cultured neurons. Representative Western blot images for SQSTM1/p62 and LC3, and graphs showing 
mean ± SEM in extracts from neuronal cultures treated or not with 0.5 μM Rapamycin for 24h  from 
control and SPLfl/fl/Nes mice (n ≥ 3; two-way ANOVA, Pp62,genotype < 0.0001, Pp62,treatment = 0.0174, PLC3,genotype 
= 0.0105, PLC3,treatment = 0.0151). 
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3.4 Altered presynaptic morphology in hippocampal CA1 region of SPLfl/fl/Nes  mice 
Based on previous results on S1P neurotoxicity (Hagen et al. 2011), we tested whether brains of 
SPLfl/fl/Nes mice exhibit neuronal loss. In a first straight forward approach a neuron-specific 
nuclear protein (NeuN) immunohistochemical staining of coronal brain sections was performed. 
Although we did not observed massive neuronal loss (Fig. 11 A), closer quantitative examination 
of brain sections revealed a reduced thickness of the dentate gyrus in SPLfl/fl/Nes mice (Fig. 11 B). 
Neuropatholological processes are often accompanied by reactive gliosis or reactive astrogliosis, 
a term coined for the morphological and functional changes seen in astroglial cells/astrocytes 
(Pekny et al. 2014). We therefore performed immunohistochemical stainings using GFAP (glial 
fibrillary acidic protein) antibody and detected an age-dependent increase of reactive astrogliosis 
in the cortex of SPLfl/fl/Nes mice (Fig. 11 C). Western immunoblotting confirmed an age-
dependent increase of GFAP, indicative for reactive astrogliosis in SPL-deficient brains (Fig. 11 
C). These gross irregularities in the hippocampal region was further investigated by Dr. Oleg 
Shupliakov at the subcellular morphology of asymmetric (excitatory) synapses in the 
hippocampal CA1 region in SPLfl/fl/Nes mice (Mitroi et al. in press). Analysis of ultrathin sections 
revealed a significant decrease in number and density of synaptic vesicles in nerve terminals from 
SPLfl/fl/Nes mice compared to controls (Mitroi et al. in press). 
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Figure 11. The impact of SPL ablation on brain morphology. A, Neuron-specific nuclear protein 
(NeuN) immunohistochemistry of coronal brain sections from 18-month-old control and SPLfl/fl/Nes mice (4 
animals per group). Scale bar, 500 µm. B, Dentate gyrus from 6-month-old control and SPLfl/fl/Nes mice (3 
animals per group) stained with DAPI (blue) and Nissl (green) (unpaired t test, P = 0.0014). C, 
Immunohistochemical staining of 18-month-old mice (unpaired t test, P = 0.0076) and western blot 
analysis of control and SPLfl/fl/Nes mice of the indicated age with anti-GFAP (glial fibrillary acidic protein) 
antibody reveals reactive astrogliosis  in the cortex of SPLfl/fl/Nes mice (two-way ANOVA, Pgenotype < 
0.0001; Ptime = 0.0005). Scale bar, 50 µm. 
 
3.4.1 Altered expression of presynaptic proteins in SPLfl/fl/Nes mice  
Next, we aimed to identify the molecular mechanism underlying the observed alterations in 
synaptic morphology in SPL-deficient mice. First we assessed whether the reduced number of 
synaptic vesicles or/and sphingosine which has been shown to facilitate SNARE complex 
assembly and to activate synaptic vesicle exocytosis (Darios et al. 2009) is also reflected in the 
expression of presynaptic proteins. We found that in hippocampi as well as in cultured cerebellar 
neurons of SPLfl/fl/Nes mice the expression of the presynaptic markers Bassoon and Synapsin-1 as 
well as the SNARE-proteins syntaxin and VAMP2 and the major synaptic vesicle protein 
synaptophysin was significantly decreased (Fig. 12 A-E). However, the expression of other 
presynaptic proteins including synaptotagmin, piccolo, SNAP25, MUNC18 and NCS1 was not 
affected (Fig. 13 A-E). The expression of the post-synaptic marker PSD-95 (Fig. 12 F) and other 
proteins including IDE (insulin degrading enzyme) (Fig. 13 F) and GAP-43 (Fig. 13 G) was not 
affected in SPLfl/fl/Nes mice. Similar results were obtained in cultured cerebellar neurons of 
SPLfl/fl/Nes mice (Fig. 12 G-H).  
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Figure 12. Expression of presynaptic proteins is reduced in SPLfl/fl/Nes mice. Protein amounts were 
assessed by (A – F) immunoblotting , (unpaired t test, PBassoon = 0.0002, PSynapsin-1 < 0.0001, Psyntaxin 1 = 
0.0157, PVAMP2 = 0.0048, PSynaptophysin = 0.0099). Immunostaining of the presynaptic marker proteins (H) 
Bassoon and (I) synaptophysin in cerebellar granule cells after 2 weeks in culture. F-actin (red), bassoon 
and synaptophysin (green). 
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Figure 13. Proteins with unchanged expression in SPLfl/fl/Nes mice. (A – G) Protein amounts were 
assessed by immunoblotting. 
 
3.4.1.1 Unaltered expression of mRNA of presynaptic proteins in SPLfl/fl/Nes mice 
Since S1P was shown to modulate the activity of histone deacetylases (Hait et al. 2009), we 
checked whether the decreased expression of presynaptic proteins occurred at transcriptional 
level. Yet, no changes in transcript amounts were found in brains of SPLfl/fl/Nes mice (Fig. 14). 
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Figure 14. mRNA levels of presynaptic proteins in SPLfl/fl/Nes mice. Transcript amounts were 
determined by qRT-PCR in hippocampi of 6-month-old mice. 
 
3.4.2 The ubiquitin-proteasomal system is up-regulated in SPLfl/fl/Nes mice   
As many presynaptic proteins are known to be degraded by the UPS (Bingol et al. 2005, Hegde 
2010), and there is a coordinated balance of protein ubiquitination, proteasomal activity and 
autophagy (Nedelsky et al. 2008, Korolchuk et al. 2010, Riley et al. 2010), we next assessed 
protein ubiquitination and proteasomal activity in SPLfl/fl/Nes brains. The amount of ubiquitinated 
proteins was indeed considerably elevated in brains of SPLfl/fl/Nes mice compared to the respective 
age matched controls (Fig. 15 A).  Moreover, augmented protein ubiquitination was associated 
with increased proteasomal activity (Fig. 15 B). In addition, we found that presynaptic proteins 
with reduced expression were indeed included in the highly ubiquitinated protein fraction (Fig. 
15 C). 
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Figure 15. Ablation of SPL leads to an elevation of proteasome activity. Experiments were performed 
in brains of SPLfl/fl/Nes mice at the indicated ages. (A) Age-dependent increase of ubiquitinated proteins 
(two-way ANOVA, Pgenotype = 0.0058, Ptime = 0.0284). (B), increase of proteasomal activity (two-way 
ANOVA, Pgenotype = 0.0058). (C) immunoprecipitation of ubiquitinated proteins followed by Western 
blotting of synapsin-1 (unpaired t test, PSynapsin-1 = 0.0354). 
 
3.4.2.1 Decrease of deubiquitinating protein USP14 in SPLfl/fl/Nes mice 
The proteasome-associated deubiquitinating enzyme USP14 on one hand is functionally coupled 
with proteasomal activity and on the other hand a critical regulator of synaptic plasticity 
(Kowalski et al. 2012). The loss of USP14 causes a large reduction in the number of synaptic 
vesicles and impairs paired pulse facilitation (PPF), indicating that UPS14 regulates presynaptic 
structure and function (Walters et al. 2014). We therefore studied the expression of USP14 at 
protein and mRNA level in SPLfl/fl/Nes mice. As depicted in Figure 16 A the expression of USP14 
was considerably reduced in hippocampi of SPLfl/fl/Nes mice. However, there were no significant 
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differences in the amount of the respective transcripts (Fig. 16 B). On the other hand USP14 was 
included in the highly ubiquitinated protein fraction, suggesting that its decreased expression 
could be due to its degradation by the proteasome (Fig. 16 C). 
 
Figure 16. Ablation of SPL leads to a decreased expression of USP14. Experiments were performed in 
brains of SPLfl/fl/Nes mice at the indicated ages. (A) expression of USP14 (two-way ANOVA, Pgenotype < 
0.0001). (B) transcript levels of USP14. (C) immunoprecipitation of ubiquitinated proteins followed by 
Western blotting of USP14 (unpaired t test, PUSP14 = 0.0231). 
 
3.4.2.2 Proteasome inhibition restores expression of USP14 and of presynaptic proteins  
To test whether slowing protein degradation would restore the changes in protein expression in 
the hippocampus of SPLfl/fl/Nes mice, hippocampal slices were treated with the proteasome-
specific inhibitor epoxomicin for 5h, restoring the decreased expression of USP14 and the 
SNARE-proteins, syntaxin1 and VAMP2, in SPLfl/fl/Nes mice with no significant effect in controls 
(Fig. 17 A). Presynaptic proteins were also restored upon treatment with MG-132 for 24h in 
cultured cerebellar neurons from SPLfl/fl/Nes mice (Fig. 17 B, 18).  
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Figure 17. Proteasome inhibition restores expression of USP14 and of presynaptic proteins in 
SPLfl/fl/Nes mice. A, Hippocampal slices from control and SPLfl/fl/Nes mice were incubated in the absence or 
presence of 15 µM epoxomicin (Epoxo) for 5 h, immunoblotting of USP14 and SNARE-proteins (two-
way ANOVA, PUSP14 = 0.0125, PSyntaxin 1 = 0.0315, PVAMP2 = 0.0390). B, Neuronal cultures generated from 
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cerebella of mice with the indicated genotype were incubated at day 14 in culture with 10 µM proteasomal 
inhibitor MG-132 for 24 h, immunoblotting (two-way ANOVA, PSynaptophysin = 0.012, PSynapsin-1 = 0.0095).  
 
 
Figure 18. Proteasome inhibition restores expression of presynaptic proteins in SPLfl/fl/Nes mice. 
Immunostaining. F-actin (red), synaptophysin and synapsin-1 (green). 
 
3.4.2.3 Proteasome activity is re-established by BAPTA-AM in SPLfl/fl/Nes mice  
As calcium is a potential inducer of the UPS (Uvarov et al. 2008), and there is evidence that S1P 
accumulation induces calcium release from the ER (Hagen et al. 2011), the effect of calcium 
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chelation on UPS was assessed. Indeed addition of BAPTA-AM, a calcium chelator, completely 
re-established proteasomal activity in neurons derived from SPLfl/fl/Nes mice. (Fig. 19).  
 
Figure 19. Proteasomal activity is normalized by calcium chelation in SPLfl/fl/Nes mice. Neuronal 
cultures were incubated in the presence of the calcium chelator BAPTA-AM (5 µM, 1 h) (two-way 
ANOVA, P = 0.0003).  
 
3.5 SPLfl/fl/Nes mice exhibit deficits in spatial learning, memory and motor coordination 
Based on all the changes regarding brain morphology, physiology and biochemistry described 
above we decided that it is very important to find out whether cognitive skills and motor 
coordination of SPLfl/fl/Nes mice are also affected. We started by analyzing in parallel exploratory 
activity in an open field of SPLfl/fl/Nes and control littermates.  As illustrated in Figure 20 A no 
significant difference in the distance covered by control and SPLfl/fl/Nes mice could be detected. 
Next, we tested spatial learning and memory in an object-place-recognition task in the SPLfl/fl/Nes 
and control mice (Fig. 20 B, C). During training trials (3 x 6 min), mice were allowed to explore 
two identical objects situated in defined locations of arena. During the test, the position of one of 
the objects was shifted to a new location, while the other object remained in the known location. 
Total exploration times (new object + known object) did not differ during the test between 
experimental groups, indicating that the overall levels of exploratory activity were similar 
between SPLfl/fl/Nes mice and controls. There was, however, a difference in exploration patterns 
between genotypes: Controls spent significantly more time exploring the object in the novel 
location compared to the object in the known location, which is indicative of memory for the 
prior object locations during training. SPLfl/fl/Nes mice, in contrast, did not spend more time 
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exploring the objects in the familiar and novel locations and, hence, lacked evidence for proper 
object-place memory (Fig. 20 B, C). We also examined spatial learning and memory in a hidden 
version of the Morris water maze in SPLfl/fl/Nes and control mice. Shown are quadrant occupancy, 
target crossings and proximity in the probe trial at day 7 (Fig. 20 D-F). Note that escape latencies 
did not differ between the two groups (not shown). Moreover assessment of associative learning 
and memory in a contextual fear conditioning paradigm indicated reduced performance in 
SPLfl/fl/Nes mice as judged by higher activity suppression ratios compared to controls (Fig. 20 G). 
Finally, we examined motor coordination and balance with the accelerating rotarod, which 
revealed severe impairments in SPLfl/fl/Nes mice (Fig. 20 H). Altogether, these data demonstrate 
the presence of profound and complex neurological phenotypes in SPLfl/fl/Nes mice. 
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Figure 20. Profound deficits in spatial learning, memory and motor coordination in SPLfl/fl/Nes mice. 
A, Open field test: Exploratory activity is expressed as the distance covered during 20 min. B, Object 
placement recognition test; shown is the exploration time of the objects in the novel and familiar location, 
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respectively (two-way ANOVA, P = 0.0265). C, Novel object recognition ability; shown is the 
discrimination index, represented by the normalized ratio of time spent with the novel object and the 
familiar object (unpaired t test, P = 0.0097). D, Fear conditioning test. Shown is the relative time of 
activity expressed as the activity suppression ratio [(time of activity during test)/(time of activity during 
test + time of activity during baseline)]. Baseline activity was determined 2 min before aversive stimulus 
whereas time of activity was determined one day after associative training in a context fear conditioning 
paradigm (unpaired t test, P = 0.0053). E-G, Hidden version of the Morris water maze; TQ, target 
quadrant with hidden platform; OQ, other quadrants. E: Time of quadrant occupancy (two-way ANOVA, 
P = 0.001); F: Number of target crossings after completion of training (two-way ANOVA, P = 0.001). G: 
Time spent in the target area expressed as distance from the target (two-way ANOVA, P = 0.043) . H, 
Latency to fall in the context of a motor coordination test on the accelerating rotarod (two-way ANOVA, 
P < 0.0001) . All tests were assessed in mice at an age of 15-18-month with n=9 (control group), and n=10 
(SPLfl/fl/Nes group). 
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4. DISCUSSION 
 
 
The generation of a mouse model with neural specific ablation of SPL and the consequent 
accumulation of S1P and sphingosine leads to morphological, molecular, and behavioural 
abnormalities. Moreover, it has allowed us to identify a formerly overlooked direct role of SPL in 
neuronal autophagy.  
On the one hand accumulation of S1P and sphingosine induced a calcium mediated elevation of 
the UPS and hence reduced expression of several presynaptic proteins. The inhibition of 
proteasomal activity restoring protein expression suggests the UPS as a possible link connecting 
sphingolipid metabolism and presynaptic pathology. On the other hand our results show that SPL 
deficiency blocks autophagy at its early stages because of reduced PE production.  
 
4.1 The effects of SPL deficiency  
Synaptic pathology has been acknowledged as a key early event in neurodegeneration, and 
presynaptic terminal changes during ageing and neurodegeneration have been reported (Wishart 
et al. 2006, Yasuda et al. 2013).  However, the detailed mechanisms connecting sphingolipid 
metabolism to synaptic dysfunction remain poorly understood and the existing reports on the 
connection between S1P, sphingosine and synaptic function are rather contradictory (Kanno et al. 
2010, Kanno et al. 2011, Chan et al. 2012, Chan et al. 2012, Kempf et al. 2014). Earlier reports 
argue for a positive role of S1P in synaptic transmission (Kanno et al. 2010, Kanno et al. 2011, 
Chan et al. 2012, Chan et al. 2012). In contrast, a recent report demonstrated a repressive effect 
of S1P signalling on synaptic plasticity (Kempf et al. 2014). Consistently, our results argue in 
favour of S1P and sphingosine accumulation leading to perturbations in synaptic morphology and 
function. Hence S1P can be viewed as a double edged sword wherein, despite its importance in 
normal cellular functions, both decrease and increase of the lipid beyond a threshold might be 
fatal for cellular functions. Reports regarding the function of enzymes involved in S1P 
metabolism are also controversial. There are two isoforms of sphingosine kinases (SK1 and SK2) 
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that generate S1P (Pitson 2011). Presynaptic SK1-derived S1P was reported to promote 
neurotransmitter release in hippocampal neurons (Kajimoto et al. 2007) and C. elegans (Chan et 
al. 2012), while studies in human and rodent brain suggest that SK2 is particularly important in 
neurons (Blondeau et al. 2007, Katsel et al. 2007). However, the major regulator of intracellular 
S1P levels is S1P-lyase (SPL). It catalyses the irreversible cleavage of S1P to hexadecenal and 
ethanolamine phosphate, the final step of sphingolipid catabolism (Serra et al. 2010). 
We show that loss of SPL activity results in tissue-dependent accumulation of S1P and 
sphingosine. Similar results were also reported by others (Hagen et al. 2009, Bektas et al. 2010, 
Hagen-Euteneuer et al. 2012). Intriguingly, SPL-deficiency in neurons causes a predominant S1P 
accumulation and to a lesser degree, its metabolic precursor sphingosine with no significant 
alterations in ceramide, sphingomyelin and glycosphingolipids (Hagen-Euteneuer et al. 2012).  
Neurodegenerative disorders are characterized by the loss of structure and function of specific 
neuronal circuitry in the brain. Behavioural science plays an important role when characterizing 
mouse models of human disorders. Therefore, standard test for assessing behavioural changes are 
used (Dumont 2011). The alterations in behaviour observed in the present study were 
accompanied by morphological and functional changes of hippocampal synapses (Mitroi et al. in 
press). Vesicle pools were largely reduced (60 %) and single vesicles were increased in diameter 
(Mitroi et al. in press). A major finding in the study by Walters et al. (Walters et al. 2014) was 
that the loss of presynaptic USP14 triggers a large reduction in the number of presynaptic 
vesicles including docked vesicles. Since the number of docked vesicles has been shown to 
correspond to the size of the readily releasable pool (Dobrunz et al. 1997, Schikorski et al. 2001), 
that is assumed to be reduced in stimulated synapses. Note that based on the known effects of 
increased calcium levels on endocytosis (Cousin et al. 2000, Wu et al. 2009) an increased 
recycling and delivery of vesicles to release sites may be expected. In agreement with this, no 
difference in the number of “docked” vesicles was detected in synapses at rest (Mitroi et al. in 
press). Moreover, an increased number of coated endocytic vesicles were observed in the 
SPLfl/fl/Nes mice (Mitroi et al. in press). Additional role of endocytosis and calcium on increased 
size of synaptic vesicles in hippocampi of SPLfl/fl/Nes mice remains unclear.   
Astrocytes are ubiquitous glia and provide many supportive activities crucial for neuronal 
function in uninjured central nervous system (CNS) (Kimelberg et al. 2010), and most likely the 
                                                                                                                    Discussion 
75 
 
modeling and maintenance of synapses (Ullian et al. 2001). Astrocytes become “reactive” in 
response to all CNS insults. Evidence of neuroinflammatory processes has been found in several 
neurodegenerative diseases, like Alzheimer’s disease, Parkinson’s disease, Huntington’s disease 
and multiple sclerosis (Glass et al. 2010). Although substantial information regarding molecules 
that are able to induce reactive astrocytosis is available, the degree to which reactive astrocytes 
augment, maintain, or down-regulate the supportive activities when they become reactive is not 
known (Sofroniew 2005). Another function of astrocytes is the uptake of glutamate, which is the 
main route of glutamate removal, from glutamatergic synapses, conversion of glutamate to 
glutamine, and in the last step re-uptake of glutamine by presynaptic neurons to reconstitute 
neurotransmitter pools (Colangelo et al. 2014). Therefore, the upregulation of reactive astrocytes 
seen by an increased GFAP expression in the SPLfl/fl/Nes mouse brain may be due to the 
presynaptic changes, although there was still no significant neuronal death. 
 
4.2 SPL involvement in autophagy 
Studying the enzymes regulating S1P balance is a promising route to understand S1P regulated 
autophagic mechanisms (Lavieu et al. 2006, Lepine et al. 2011, Moruno Manchon et al. 2015). In 
neurons cytosolic SK1 responsible for S1P generation was shown to enhance flux through 
autophagy whereas S1P-degrading enzymes like SPPs or SPL decrease this flux (Moruno 
Manchon et al. 2015). In non-neuronal cells SK1 (S1P)-induced autophagy is nutrient sensitive 
and characterized by the inhibition of mammalian target of rapamycin (mTOR) (Lavieu et al. 
2006). Alternatively, deletion of SPP1 has been shown to induce autophagy even in the presence 
of nutrients via an mTOR independent mechanism.  Notably, several studies have described 
extrinsic S1P acting via its receptors as an inhibitor of autophagy through activation of the mTOR 
pathway (Maeurer et al. 2009, Taniguchi et al. 2012).  
PE production from ethanolamine phosphate resulted from the breakdown of S1P could not 
constitute the major pathway for de novo synthesis, since there are other S1P-independent 
pathways for the synthesis of ethanolamine phosphate and/or PE (Rockenfeller et al. 2015). The 
precise control and regulation of sphingolipids is a complicated process and even slight changes 
in the concentration of these metabolites can inflict distinct and opposing effects on cellular 
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functions (Merrill 2002). The necessity for such an intricate regulation is also argued to be a 
reason behind why S1P degradation is not a predominant source of ethanolamine phosphate 
(Hannun et al. 2001). However, our findings concerning SPLfl/fl/Nes mice indeed point to an 
important role for PE generated from the S1P degradation products in autophagy and lysosomal 
function at least in neurons. Of note, an earlier study by Zhang et al. (Zhang et al. 2007) has 
shown evidence for a striking remodeling of the sphingolipid pathway for bulk production of 
ethanolamine in Leishmania (Zhang et al. 2007). On the other hand, a recent report by 
Rockenfeller et al. (Rockenfeller et al. 2015) has shown that the artificial increase of intracellular 
PE levels or overexpressing the PE-generating phosphatidylserine decarboxylase Psd, 
significantly increased autophagic flux which in turn extended the life span of yeast 
(Rockenfeller et al. 2015). Taken together, these findings establish on one hand the importance of 
PE in the autophagic pathway and on the other hand the significant contribution of S1P 
metabolism in regulating this pathway. Thus  SPL apart from linking sphingolipid and 
glycerophospholipid metabolism (Kihara 2014) might also modulate autophagic flux via its 
reaction product ethanolamine phosphate in tissues which abundantly express sphingolipids as 
demonstrated here for neurons.  
On a closer look, it is obvious that there are more layers of complexity to our results than they 
appear to be at the first glance. A bidirectional effect of SPL ablation leading to the reduction of 
its product ethanolamine phosphate and also the accumulation of its substrate S1P can be 
envisaged. S1P has its own specific routes through which it can influence autophagy. S1P 
treatment has been shown to counteract autophagy induction by amino acid starvation and this 
effect was mediated by the S1PR3 in an mTOR dependent manner (Taniguchi et al. 2012). It is to 
be noted that mTOR independent effects of S1P on autophagy have also been documented 
(Lepine et al. 2011) and these differences could be attributed to the extrinsic and intrinsic effects 
of S1P (Taniguchi et al. 2012). Our results show an mTOR independent effect as rapamycin 
treatment could not rescue the accumulation of p62 and the decreased conversion of LC3-I into 
LC3-II. Importantly, rapamycin increased LC3 levels and decreased p62 levels in control 
neurons. Nevertheless it was shown in earlier reports that accumulation of SK2-derived S1P 
induces ER stress (Hagen et al. 2011, Hagen-Euteneuer et al. 2012) known to up regulate cellular 
autophagy (Yang et al. 2010, Wang et al. 2016). At the same time accumulating S1P reduced 
neuronal de novo sphingolipid biosynthesis (Hagen-Euteneuer et al. 2012), which was reported to 
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be essential for induction of autophagy in non-neuronal cells (Sims et al. 2010). In line with this 
data, we detected both, an accumulation of p62, a generally accepted indicator of impaired 
autophagy (Rusten et al. 2010) as well as an elevated expression of beclin-1 and Atg5-Atg12 
complex, which is rather indicative of increased autophagosome initiation (Yang et al. 2010). 
Moreover, pharmacological inhibition of SPL by 2-acetyl-4-(tetrahydroxybutyl)imidazole (THI) 
under conditions of vitamin B6 deficiency was able to produce the same phenotype of autophagy 
impairment. Accumulation of p62 was prevented by PE supply implying that an effect of S1P on 
autophagy in SPL-deficient neural tissue if present is rather secondary. Intriguingly, in Niemann-
Pick disease type C1 caused by an impaired cholesterol trafficking and hence lysosomal storage 
of sphingolipids, autophagy was also found to be both induced and defective (Elrick et al. 2012, 
Ordonez et al. 2012). 
Another possibility that cannot be fully excluded is the role of sphingosine in autophagy which is 
also accumulating to a certain extent in SPL-deficient neurons (Hagen-Euteneuer et al. 2012). 
Sphingosine has recently been demonstrated to trigger calcium release from acidic stores 
(Hoglinger et al. 2015) that in turn might activate autophagy. Intriguingly, our results regarding 
LAMP-2 and cathepsin D point to an increased lysosomal function. It could be assumed therefore 
that augmented lysosomal activity downstream of the autophagic block as well as enhanced 
number of phagophores upstream of this block might represent an attempt of SPL-deficient 
neurons to overcome impaired autophagy caused by reduced PE levels.  
Defective autophagic flux and lysosomal activity are involved in the pathogenesis of 
neurodegenerative diseases (Nixon 2013, Menzies et al. 2015) by causing defective degradation 
of protein aggregates. Consistent with this hypothesis, we observed an accumulation of 
neurodegenerative biomarkers of Alzheimer’s disease and Parkinson’s disease in SPL-deficient 
mouse brains. A strong accumulation of APP and potentially amyloidogenic APP C-terminal 
fragments, as well as an increased generation of Aβ have been reported before in SPL-deficient 
mouse embryonic fibroblasts (Karaca et al. 2014). 
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4.3 Molecular mechanisms of neurodegeneration triggered by SPL ablation 
Deletion studies have helped to identify presynaptic proteins which are essential for synaptic 
function and integrity.  Removal of such key proteins often leads to impaired neurotransmitter 
release, changes of the vesicle pools or cytomatrix at the active zone. However, in some cases the 
loss of function can be compensated by other presynaptic proteins (Gundelfinger et al. 2012, 
Sudhof 2012, Sudhof 2013). On analyzing the levels of selected key proteins involved in 
different stages of the vesicle cycle, we found that several of these proteins were reduced in 
SPLfl/fl/Nes mice. Since we did not observed morphological changes in the active zone we 
conclude that the observed reductions in key proteins do not underlie or at least are not sufficient 
(Arancillo et al. 2013) to cause the observed changes in synaptic transmission in SPLfl/fl/Nes mice 
(Mitroi et al. in press). At the structural level a reduction in number of synaptic vesicles in the 
pool has been reported in synapsin I and synapsin triple-knockout mice (Li et al. 1995, Siksou et 
al. 2007). Accordingly, a profound reduction in number of vesicles has been reported also in a 
study of Mitroi et al. (Mitroi et al. in press). A redistribution of synapsin has been recently 
reported following application of S1P in nanomolar concentration to synapses (Riganti et al. 
2016) thus supporting that this protein is the target of S1P action. 
Speese et al. (Speese et al. 2003) have shown that parts of the ubiquitin proteasome system (UPS) 
are present in the presynaptic terminal and that UPS acutely regulates presynaptic protein 
turnover modulating synaptic efficiency and neurotransmission strength. Moreover, acute 
pharmacological inhibition of the proteasome causes a rapid strengthening of neurotransmission 
by 50 % because of increased presynaptic efficacy (Speese et al. 2003). According to a previous 
study of Speese et al. (Speese et al. 2003) in the SPLfl/fl/Nes mice there is an increase in 
proteasomal activity and a decrease of several presynaptic proteins. Pharmacological inhibition of 
proteasomal activity rescued presynaptic proteins and USP14 expression in SPLfl/fl/Nes mice. We 
therefore propose the degradation of USP14 by UPS could be the underlying molecular 
mechanism responsible for the morphological and behaviour impairments observed. Localized in 
the 19S regulatory subunit of the proteasome, USP14 has been proposed as a negative modulator 
of proteasome-mediated degradation (Lee et al. 2010).  
Certain studies suggest a compensatory mechanism between UPS and autophagy allowing cells 
to reduce the accumulation of UPS substrates. This observation is referring to an increased 
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function of autophagy due to the impairment of the UPS (Iwata et al. 2005, Ding et al. 2007, 
Pandey et al. 2007). However the reverse mechanism is not available since a deficiency in 
autophagy leads to accumulation of polyubiquitinated proteins with no alteration in proteasome 
function (Hara et al. 2006, Komatsu et al. 2006). Hence, we cannot exclude that the increase of 
ubiquitinated proteins observed in the brains of SPLfl/fl/Nes mice could be a result of autophagy 
alteration. Notably, p62, an autophagic marker, is increased in the brains of SPLfl/fl/Nes mice. p62 
competes with other ubiquitin-binding proteins for binding to ubiquitylated proteins (Korolchuk 
et al. 2009). When is accumulating, p62 oligomerizes, preventing the delivery of the p62-bound 
ubiquitylated proteins to the proteasome for degradation (Korolchuk et al. 2010). This might be a 
good explanation for the accumulation of ubiquityled proteins in spite of the fact that the 
proteasomal function is activated in SPLfl/fl/Nes mice. The enhancement of proteasomal activity 
might be a consequence of increased cytosolic Ca2+ (Uvarov et al. 2008) due to the ER-stress 
caused by high levels of S1P and sphingosine (Hagen et al. 2011, Hagen-Euteneuer et al. 2012).  
Our results indicate an important role of proteasomal activity and hence deregulated protein 
degradation at the presynapse induced by SPL deficiency. Although, we cannot conclusively 
pinpoint the exact underlying molecular mechanism, our results, which are in line with recent 
findings of Jarome et al. (Jarome et al. 2014), suggest that the decrease of USP14 by the elevated 
UPS activity might be the central switch that propagates the observed long-term memory 
impairment for the fear conditioning task in  SPLfl/fl/Nes mice, making USP14 an important 
regulator of long-term memory formation. Since presynaptic dysfunction might be an early 
pathogenic event in neurodegeneration (Zhang et al. 2009), our findings could have important 
implications for diseases where S1P analogues are used as disease modifying therapies.  
In addition to earlier data providing a calpain mediated link that connects S1P and 
neurodegeneration (Hagen et al. 2011) the present study provides an additional route that 
connects SPL deficiency and neurodegeneration via a PE-mediated defective autophagy 
mechanism. 
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CONCLUSIONS 
 
 
Our results demonstrate an involvement of sphingolipid metabolism in maintaining presynaptic 
nerve terminal architecture leading to cognitive deficits. We are the first to observe that S1P 
accumulation is essential for the assessed elevation of ubiquitin-proteasomal system (UPS) which 
is responsible for the decrease of several presynaptic proteins and the deubiquitinating protease 
USP14. The latter was shown to play a critical role in synaptic plasticity and its loss is associated 
with several physiological impairments in the central nervous system (Kowalski et al. 2012). The 
inhibition of proteasomal activity restoring protein expression suggests the UPS as a possible link 
connecting sphingolipid metabolism and presynaptic pathology. Since presynaptic dysfunction 
might be an early pathogenic event in neurodegeneration (Zhang et al. 2009), our findings could 
have important implications for diseases where S1P analogues are used as disease modifying 
therapies. 
Our study brings further insights for another important aspect of S1P mediated autophagy 
regulation, which has not been investigated so far; the role of the SPL degradation product 
ethanolamine phosphate. The latter is easily incorporated into PE, which is important for 
autophagosome initiation and elongation. We were able to see a decrease in PE, followed by an 
impaired autophagy and a consequent accumulation of neurodegenerative biomarkers in the mice 
with neural specific ablation of SPL. Our results show that PE paucity is leading to the blockage 
of autophagic flux at the early stages of autophagosome formation. These findings identify a 
formerly overlooked direct role of SPL in neuronal autophagy that could be of great interest in a 
better understanding of neurodegenerative diseases in which autophagy is dysfunctional. 
However, the detailed mechanism involved in the regulation of autophagy by PE linked via SPL 
to S1P metabolism is yet to be explored. 
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